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1. Introduction
Testosterone (T) is one of the most important naturally circulating steroid hormones. Exerting
both androgenic and anabolic activities it is secreted into the blood and in men is produced pri‐
marily by the testes. In women, by contrast, production occurs in the ovaries and particularly
from peripheral conversion of the T precursors androstenedione, DHEA and DHEA-S (Bur‐
ger, 2002). T is no longer regarded as a male only hormone, and similarly estradiol is no longer
a female only hormone (Fausto-Sterling, 2000). While it is true that men generally have higher
levels of T and lower concentrations of oestrogen and progesterone than women, all these sex
steroid hormones play essential roles in both sexes (Ullis et al., 1999).
Testosterone has now been well established as having an essential function in wide-ranging
areas of female health. For example, it is an important determinant of female sexuality, criti‐
cal for development and maintenance of bone mineralisation, contributes to menstrual cycle
regulation and to behavioural changes in premenstrual syndrome (Bachmann & Leiblum,
1991; Slemend et al., 1996). Therefore, T and other androgen replacement therapies in wom‐
en with or without oestrogen have become widely recommended for a variety of women ex‐
periencing androgen deficiency syndrome (Somboonporn et al., 2006; Hickok et al., 1993).
It has been shown that sex hormones levels can be influenced by diet, exercise, age, BMI,
ethnicity and others (Allen & Key, 2000; Kraemer et al., 1998). Various studies have suggest‐
ed that increasing dietary fibre intake could influence total and/or bio-available T and oes‐
tradiol levels (Rock et al., 2004) or T and SHBG levels (Longcope et al., 2000). Recently,
Wang et al. (2005) reported that a low-fat high-fibre diet decreased serum and urine andro‐
gens in men. The majority of these studies on T were conducted in men and the data pub‐
lished were conflicting. These equivocal findings resulted, at least in part, from different
study designs and protocols (fibre content and type, subject compliance, lack of control af‐
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fecting other dietary components) and the complex mechanisms involved in steroid metabo‐
lism. Subsequently, we have performed a pilot study to investigate the effect of increasing
dietary fibre and found a moderate increase in urinary T excretion of healthy women taking
a mixed high fibre diet for two weeks (unpublished observations), suggesting a potential
correlation between dietary fibre intake and androgen status. This could be due to an effect
on the enterohepatic cycle as hypothesised by some investigators in delaying the excretion
of steroids and hence a modest increase in plasma and urinary levels (Adlercreutz et al.,
1987; Groh et al., 1993). Other researchers have suggested that low-fat high-fibre diet might
indirectly increase bio-available serum androgen levels by preventing the development of
insulin resistance which is associated with reduced SHBG levels (Haffner et al., 1994; Pas‐
quali et al., 1995). Conversely, some workers proposed that low-fat high-fibre diet reduced
circulating steroid hormone concentrations due to higher faecal excretion of conjugated ste‐
roids (Pusateri et al., 1990) or an increase in the synthesis of SHBG (Berrino et al., 2001).
Quantitative determination of circulating T is possible from an assortment of biological ma‐
terial; i.e. plasma, serum, hair, saliva, and urine. However, early attempts at determining
concentrations of circulating T, primarily for clinical purposes, traditionally utilised plasma
or serum. As blood samples require time-consuming and often stressful venipuncture, ob‐
taining invasive multiple samples over a period of hours can be painful and this procedure
can be unattractive to participants (Dabbs, 1990). Moreover, measurement tends to be of the
total rather than free, biologically active, fraction of T. Faced with these challenges there has
been a growing awareness of the potential value of utilising saliva for measuring hormone
concentrations (Mandel, 1993; Collins, 2000). Consequently, the use of saliva as a diagnostic
tool in clinical and bio-behavioural research has grown significantly during the last two dec‐
ades (Quissell, 1993). However, salivary T measurements can be markedly influenced dur‐
ing the process of sample collection with interference effects caused by mucu-
polysaccharides and leakage of blood into saliva, storage conditions and random daily
fluctuations (Granger et al., 2004).
There are limited data establishing normal androgen values for women at different ages,
thus hampering the ability to define those with androgen deficiency (Guay, 2002), and there
is definitely a clear need for additional information on normal reference ranges of female T
levels at different age groups. Moreover, little is known about detailed daily patterns in fe‐
male T throughout the menstrual cycle (Davis, 1999). One of the aims of this review article is
therefore to discuss the importance of estimating salivary T in women and the challenges
posed by its measurement in female saliva, including a summary of our in-house ELISA
technique and the optimisation needed for the estimation of salivary T. We also discuss fe‐
male salivary T circadian dynamics showing our own data in this regard. Finally, we would
like to highlight the importance of sampling protocol; multiple female salivary T sampling
versus single saliva sampling.
2. Role of testosterone in women’s health and well-being
Whilst androgens are known to play a significant role in wide-ranging aspects of male
health (Nieschlag, 1998; Isidori et al., 2008), there is an increasing realisation that they are
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also critical for mental and sexual health as well as physical well-being in females (Christi‐
ansen, 2004; Davis & Tran, 2001). The following examples provide a non-exhaustive illustra‐
tion of testosterone significance for females.
2.1. Epidemiology and clinical importance of abnormal testosterone levels in females
Female sexual dysfunction is thought to affect over 40% of women in the United States, ac‐
cording to a study by Laumann and colleagues (1999). As experts evaluate women with po‐
tential sexual interest disorders, there is a growing body of literature to guide them in how
to understand, diagnose and treat these problems. Androgens are known to be involved in
women’s arousability, response, intensity and ease of orgasm, as well as in initial spontane‐
ous desire, the active neurovascular smooth muscle response of swelling, increased lubrica‐
tion and genital sexual sensitivity. T is thought to be the most important hormone for
maintaining sex drive or libido in women and a deficiency can cause impaired sexual func‐
tion (Snyder, 2001). In this regard, T may decrease vaginal atrophy as well as inflammation,
itching and pain of the vulva (Leiblum et al., 1983). However, excessive amounts may in‐
crease the risk of endometrial cancer due to hyperinsulinemia (Ciampelli & Lanzone, 1998).
In a recent Cochrane systematic review (Somboonporn et al., 2010), it was concluded that
adding T to hormone therapy has a beneficial effect on sexual function in postmenopausal
women. However, the combined therapy is associated with a higher incidence of hair
growth, acne and a reduction in high-density lipoprotein (HDL) cholesterol. These adverse
events may vary with differing doses, routes of T administration and individual differences.
Reflecting on the theoretical and conceptual challenges of relating specific hormone levels to
behaviour, there is no doubt that a relationship has not been established between levels of T
and symptoms of sexual dysfunction in women. In the brain, T has a role in maintaining
mood and memory. Indeed, high levels of T exert a significant negative effect on mood, per‐
sonal sense of well being, interpersonal relationships, self-confidence and self-worth, and
depression is a major symptom associated with low levels in women (Sands & Studd, 1995).
In the heart, T has relaxing (vasodilating) effect on coronary arteries (Sarrel, 1998; White et
al., 1998), and thus, it can reduce symptoms of angina. Unstable hormonal fluctuations can
be observed after menopause (Overlie et al., 1999). These fluctuations are usually associated
with increased incidence of migraine headache, obesity, mood changes and bleeding distur‐
bances in perimenopausal and postmenopausal women (Fettes, 1999; Vliet & Davis, 1991). It
has been suggested that postmenopausal women who are not receiving some T therapy may
have greater risk of developing coronary heart disease (Rako, 1998). The effects associated
with administering exogenous T are not especially straightforward however. For example,
when T is administered alone, it can increase the risk of atherosclerosis and decrease HDL
levels (Crook & Seed, 1990). Conversely, when T is administered with oestrogens, the in‐
creased risk of heart disease diminishes (Sarrel, 1998; Davis, 2011).
In the Michigan Bone Health Study (1992–1995), the authors examined the correlates of T in
pre- and perimenopausal women (i.e., age, menopausal status, body composition, and life‐
style behaviours) in aged 25–50 years (n=601). Body composition measures were found to be
significantly and positively associated with total T concentrations in a dose-response man‐
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ner (Sowers et al, 2001). Hysterectomy with oophorectomy was associated with significantly
lower T concentrations. For bones and osteoporosis, T (and the metabolite DHT) directly
stimulates receptors on the osteoblasts (bone building) cells to promote bone growth, bone
mineralisation and repair of damaged bone (Gasperino, 1995; Hui et al., 2002). In light of
this, T replacement may markedly decrease osteoporosis in postmenopausal women, and to‐
gether with oestrogens the steroids can preserve and rebuild the cartilages between bones
(Tremollieres et al., 1992). In the skin, T can improve the overall skin appearance by preserv‐
ing collagen and protecting against thinning of the skin as well as sebaceous glands activity
that lubricates the skin (Brincat et al., 1987). As we begin to more fully understand the above
actions, the therapeutic use of exogenous T in women is becoming increasingly widespread,
although not always without often unwanted side effects. Thousands of women have been
treated with T, the majority experience symptom improvement, improved sexual well-being
(Davis and Davison, 2012). Other possible beneficial effects of T therapy (reduced fracture
risk, improved cognitive and cardiovascular function), necessitate further investigation. Re‐
duced T levels have been found in bilateral oophorectomy, adrenal insufficiency, hypopitui‐
tarism, use of combination oral contraceptive pills or systemic glucocorticosteroids, and
premature ovarian failure (Fogle et al, 2007; Labrie et al, 2011).
As women age, the dramatic drop in T level is thought to result from a decline in the adre‐
nal production of T precursors, DHEA and DHEAS (Zumoff, et al., 1995; Davison et al.,
2005). This marked fall in peripheral androgens is associated with a number of conditions
including metabolic syndrome and osteoporosis (Davy & Melby, 2003). In addition, the
Women’s Health Initiative (2002) published their results from a prospective randomised
prevention trial of more than 16000 healthy postmenopausal women which was intended to
study the long term effects of HRT given as a combination of conjugated equine oestrogens
and medroxyprogesterone acetate. Although decreased risks of colorectal cancers and hip
fractures were reported, many women came off their hormone supplements and explored
alternatives because of the reported increased risk of stroke and invasive breast cancers.
Likewise, a large-scale UK study (Beral, 2003) found that current use of HRT, but not past
use, was associated with an increased risk of breast cancer. Similar to many other therapeu‐
tic agents, HRT has its benefits and risks. The public is constantly in search of alternative
forms of food or herbal supplements to alleviate menopausal symptoms or to prevent long-
term complications of ovarian failure.
2.2. Clinical contribution of monitoring salivary T in females for pathological and
physiological conditions
To date, a definite relationship has not been established between a specific level of T and
symptoms of T excess or deficiency such as sexual dysfunction in women and premenstrual
symptoms. There is no established level of free T below which a woman can be said to be
deficient, nor any level to which a woman should be restored that determines she is replete.
Thus the diagnosis of these disorders due to low testosterone remains a clinical diagnosis of
exclusion. In the absence of a reliable free /total testosterone assay the limitations of availa‐
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ble assays should be understood, and the measurement of testosterone used to exclude the
use of testosterone in women in whom therapy might result in testosterone excess.
There is a paucity of research which investigates salivary female T in pathological and phys‐
iological conditions. For this reason we would like to highlight the following examples of
clinical monitoring of female salivary T. Salivary T has been used to monitor treatment of
children with congenital adrenal hyperplasia (CAH), Salivary T was found to be a useful ad‐
ditional biochemical marker with 17OHP to indicate the levels of free T (Perry et al., 2005).
In a study comparing salivary and total plasma testosterone levels in healthy controls and
patients with Klinefelter’s syndrome (Wellen et al.,1983) provided indirect evidence that in
Klinefelter patients levels of salivary T and androstenedione correlated well with the report‐
ed free plasma levels. This suggests that measurement of salivary steroids may be useful in
evaluating endocrine function in both healthy and disease states. Monitoring the menstrual
cycle status of female athletes by salivary steroid determination following a 21km run (De
Crée et al., 1990) reported an increase of salivary T of 15.2%. These findings corroborate ear‐
lier studies, which found higher post-exercise plasma sex steroid levels.
Several studies have published data on the applicability and clinical value of salivary T
measurements for the diagnosis and follow-up of therapy of idiopathic hirsutism, late-onset
hypogonadism and androgen deficiency in end-stage renal disease (e.g. Shibayama et al.,
2009; Luisi et al., 1982; Cardoso et al., 2011). In addition, Teoh et al. (2005) and Gayriloya and
Lindau (2009) carried out physiological studies to assess population levels of salivary T in
children, adult females and males. They reported high co-operation rates with the in-house
salivary specimen collection.
3. Testosterone production and mechanisms of action in women
Circulating levels of plasma T in pre-menopausal women originate from multiple sites; the
ovaries (20-25%), adrenal cortex (20-25%) and the remainder (50-60%) from the peripheral
conversion of T precursors (androstenedione, DHEA and DHEA-Sulphate) (Burger, 2002;
Longcope, 1986; Simpson, 2002). T circulates in women with around 66-74% bound strongly
to sex hormone binding globulin (SHBG) and 24-30% bound weakly to albumin with only
about 1-3% being free in the blood (Pardridge & Demers, 1991; Vermeulen, 1998).
Under certain conditions the bio-available T dissociates from its carrier protein (mostly albu‐
min) and becomes free. Manni and colleagues (1985) indicated that albumin-bound T was
available to tissues such as the brain in conditions where the free T level was negligible and
in the absence of albumin. This hypothesis was contested by Ekins (1990) and Mendel (1989)
based on the assumption that steroids can act only through their genomic mechanism. Besch
et al. (1982) stated that only the non-protein-bound or ‘free’ fraction of a hormone, such as a
steroid enters the cell of the target tissue and interacts with its specific receptor protein. As
an adjunct to this latter point it should be noted that around 50% of pre-menopausal (and
almost 100% of post-menopausal) T is synthesised by peripheral conversion, distinct from
any endocrine function (Labrie et al., 2000). In addition, the fact that many steroids are now
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shown to exert some effects through the non-genomic pathway (see below) leads us to sup‐
pose that some actions, particularly in the female, are mediated by the albumin-bound frac‐
tion of T. Moreover, in a recent review Lepage (2006) demonstrated clearly the importance
of measuring the bio-available T as compared to total and free T. Thus, free and non-SHBG-
bound (sometimes called bio-available) T measures are likely to be the most reliable indica‐
tors of tissue exposure to T (Collins, 2000). As an adjunct, recent finding suggest that female
androgens made locally in large amounts in peripheral tissues from DHEA/S act in the same
cells where synthesis takes place (Labrie et al., 2003). It was therefore concluded that the
measurement of androgen glucuronides instead of T perhaps better reflects the androgenic
activity in women (Labrie et al., 2006).
Steroid hormones in the periphery are believed to equilibrate rapidly between tissues and
blood (Goncharov et al., 2006; Miler et al., 2004; Schurmeyer & Nieschlag, 1982). Total con‐
centrations of T in peripheral tissue and body fluids are mainly dependent upon the levels
of binding proteins such as sex hormone binding globulin (SHBG) and albumin. These bind‐
ing proteins can act as a reservoir for the steroid and protect it against extensive metabolism
of active (free) steroids during passage of the blood through the liver (Mendel, 1989). It is
now widely accepted that the free steroid form represents the biologically active fraction.
However, it is believed that the albumin bound T (bio-available) can bind to the receptor
(possibly the membrane bound) and exert its activity because the affinity of the steroid to‐
wards its receptor is far greater than its affinity to albumin (Author’s unpublished data;
Heinlein & Chang, 2002; Fix et al., 2004). In fact, T can also be regarded as a circulating pro-
hormone that can be converted either to DHT for androgenic activity or to oestradiol which
is the principal endogenous ligand for oestrogen receptors (Hiipakka & Liao,1998; McPhaul
& Young, 2001).
T, like other steroids, may exert its action in living cells by either the well-known genomic
pathway, involving hormones binding to a cytosolic receptor and subsequent modulation of
gene expression followed by protein synthesis (genomic actions). Or through pathways that
do not act on the genome (non-genomic actions) (Lösel et al., 2003). T has recently been re‐
ported to exert effects through interactions with receptors in the cell membrane (Heinlein &
Chang, 2002). Rapid effects of androgens have been shown on calcium fluxes (Guo et al.,
2002), intracellular phosphorylation cascades (Castoria et al., 2003), secretion of GnRH by pi‐
tuitary cells (Shakil et al., 2002) and others. It seems that in these cells, androgens can exert
their effect at very low concentrations that are not sufficient to stimulate gene transcription.
Androgen dynamics in women are usually controlled by 4 temporal phenomena: ovarian
function, hypothalamic-pituitary-adrenal axis, age decline of adrenal androgens and deple‐
tion of ovarian follicles after menopause (Burger & Casson, 2004). T and its precursor,
DHEA/S are now widely accepted as vital for normal female development (lower certain
body fat, maintain muscle mass, healthy-skin, boost energy levels and mood), sexual health
(substrate for oestrogen production, enhance sex drive and relieve menopausal symptoms)
(Laumann, et al., 1999; Davis & Tran, 2001) and might have a role to play in alleviating the
aging process of men and women (Kirkwood, 2005; Ullis et al., 1999).
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4. Measurement of female salivary testosterone: Challenges and problems
Quantitative determination of circulating T can be achieved utilising a variety of different
procedures such as; radioimmunoassay, luminescence immunoassay, fluorescence immuno‐
assay, enzyme-linked immunosorbant assay, gel filtration, equilibrium dialysis and centrifu‐
gal ultrafiltration for serum free T, protein precipitation, gas-chromatography mass-
spectrometry (including isotope dilution) and more recently LC/MS-Tandem
spectrophotometry (Edwards, 1985; Kemeny, 1991; Sinha-Hikim et al., 1998), each with their
own inherent strengths and weaknesses.
Once a medium in which to analyse T has been selected (saliva in this case) the question
then becomes what type of assay should be employed? Although the bewildering array of
techniques can make selecting the most appropriate test perplexing, as Edwards (1985) stat‐
ed ‘A systematic and objective approach will...indicate the most appropriate technique for
the particular application in mind’ (p.2). In both saliva and blood, RIA was until compara‐
tively recently the method of choice for determining concentrations of circulating T. Despite
a number of limitations, traditional analogue RIA is still widely used (Rosner, 2001). Several
authors, however, have ardently expressed concern that this method is insensitive at the
lower end of the T range; precisely where female salivary T falls (Sinha-Hikim et al., 1998).
This situation arises because most T RIA's were designed for the measurement of serum lev‐
els in men and thus lack the sensitivity required for the precise measurement of the low lev‐
els prevalent in women.
Even now, simple and routine methods for determining free steroid concentrations in plas‐
ma have not been fully developed and widely validated. Consequently, most current proce‐
dures involve technically demanding and time consuming centrifugal ultrafilitration or
equilibrium dialysis (Miller et al., 2004; Hammond et al., 1980; Riad-Fahmy et al., 1982);
processes which in themselves yield results with varying degrees of accuracy. In an effort to
circumvent the problem of not easily being able to measure free-T some authors use mathe‐
matical equations, such as the free androgen index, mass action formulation, or the Sode‐
gaard equation (Ho et al., 2006; Vermeulen et al., 1999). All are mathematical formulae of
varying complexity for working out the free component of T based on the measurement of
total T and, as a minimum, SHBG. However, because these equations rely on an affinity con‐
stant (SHBG in the case of T) and because estimations of the affinity constant varies widely,
there are very real problems with these approximations (Besch et al., 1982; Rinaldi et al.,
2002). As Vermuelen et al. (1999) point out, total serum T concentration is subject to varia‐
tions in the concentration of the binding proteins such as SHBG and CBG; it is not, therefore,
a reliable index of bio-available T. Faced with these challenges, there has been a growing
awareness of the potential value of utilising saliva for measuring hormone concentrations
(Mandel, 1993). Consequently, the use of saliva as a diagnostic tool in bio-behavioural and
clinical research has grown significantly during the previous two decades (Quissell, 1993).
In a variety of research arenas, accurate measurement of female free-T is widely regarded as
problematic (Matsumoto & Bremner, 2004). In a clinical paper on screening for androgen in‐
sufficiency, Guay (2002) argued that a major problem in assessing female T is the inaccuracy
of the measurements by current assays. Recent articles published by Taieb et al. (2002) and
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Herold and Fitzgerald (2003) illustrate that when measured by automated processes, T con‐
centrations may be inaccurate to the order of magnitude of 200-500%. This issue of measure‐
ment therefore acts as one potentially serious limiting factor in the confidence that we can
place in the results of hormone-behaviour studies, clinical studies and for female’s screening
before T therapy. Although, as technology advances and measurement continues to become
somewhat more straightforward there is still a need for highly sensitive, reliable, and effi‐
cient immunoassays with accessible reagents and materials for the determination of T in fe‐
males (Granger et al., 1999; Guay, 2002).
Given the difficulties associated with accurately measuring female free and bio-available T, the
enzyme-linked immunosorbant assay (ELISA) protocol has a number of features to recom‐
mend it over RIA. For example, reagents are cheap in comparison with RIA, the laboratory in
which our research is undertaken employs staff with substantial expertise in ELISA develop‐
ment, validation and trouble-shooting. Moreover, there is no hazard of radiation, and because
of the low concentrations of antigens in saliva HIV and hepatitis infections are much less of a
danger from saliva than from blood (Major et al., 1991). Indeed, unless visibly contaminated
with blood, human saliva is not considered a class 2 biohazard, affording researchers and insti‐
tutions administrative and safety benefits. As a consequence of these factors the ELISA meth‐
od stands out as the most appropriate routine method of choice for use in the majority of
research institutes conducting bio-behavioural research and clinical work on T.
There are a number of features that are required of an effective assay. As Kemeny and Chan‐
tler (1988) note, the type of assay should be closely tailored to the particular task for which it
is required; and the requirements of diagnostic laboratories are often very different than
those of bio-behavioural research laboratories. For example, in bio-behavioural studies that
require assessing chronobiological changes in the very low levels of free salivary T in fe‐
males, issues such as ease of use and speed are less important characteristics than sensitivity
and accuracy. Subsequently, one of the additional aims of this chapter is to describe the de‐
velopment, optimisation, and validation of an extremely sensitive in-house ELISA, designed
specifically for determining salivary T in women. In particular, the ELISA is evaluated for its
accuracy, specificity, and precision.
Salivary sampling regimens have several obvious and distinct advantages over blood sam‐
pling. They accommodate frequent and easy collection by non-invasive, relatively stress
free-techniques, thereby facilitating short term dynamic tests, pharmacokinetic analyses,
and studies of chronobiological changes (Riad-Fahmy et al., 1982). In addition, it has been
reported that the majority of subjects find little difficulty in salivating directly into collection
containers, providing adequate volumes (between 3mL and 5mL) for determining a steroid
hormone profile in less than 5 minutes (Dabbs, 1991). Nonetheless, a number of challenges
and problems associated with saliva methodology do exist (Granger et al., 2004). For exam‐
ple, compliance with salivary sampling protocols has been identified as a potential chal‐
lenge. Compliance to collection protocols is essential for accurate determination of T levels
in saliva and concerns amount collected, condition of sample and precautions taken prior to
collection (i.e. rinsing of the mouth, not eating etc.). In relation to collection, compliance has
been investigated by the use of an electronic monitoring device, and it was reported that on‐
ly 74% of subjects were found to comply with the sampling instructions and 26% failed at
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least once to obtain the correct saliva sample (Kudielka et al., 2003; Broderick et al., 2003).
Our own experience is that engagement with participants and the provision of detailed oral
and written instructions alongside the opportunity to practice with an investigator present
to answer questions and provide guidance ameliorates significantly issues of compliance.
Although diurnal and monthly patterns of salivary T generally parallel serum values, abso‐
lute ranges show variability across several studies. Few studies of normal individuals, con‐
trolling for known variables, such as pH, time of day, month and medications, have been
performed using the recently developed high sensitivity enzyme immunoassays, such as
those sold by Diagnostic Systems Laboratories (Webster, TX), Salimetrics (State College, PA)
and American Laboratory Products Co. (ALPCO) (Windham, NH). Below are several factors
which need to be taken into consideration either when using commercial kits or developing
in-house assay methodology.
4.1. Blood-saliva correlation
As Albumin is a small protein, with a molecular weight of approximately 69,000, it can pass
through the salivary membrane. Conversely, SHBG (to which the majority of circulating T is
bound) is a large carrier protein with a molecular weight of 150-200,000. As this steroid-bind‐
ing protein cannot pass easily through the salivary membrane, one of the advantages in using
saliva as the biological fluid in study centres would be around the claim that it contains concen‐
trations of analyte similar to, or even identical with, the non-protein bound (free) concentra‐
tions in blood (Baxendale, Reed, & James, 1980; Vittek et al., 1985; Longcope et al., 1987). These
claims generally relate to males, however. Although there are fewer studies examining this as‐
sociation in females, it has been suggested that correlations between T levels in serum and sali‐
va may be significantly lower than in males (Granger et al., 1999; Miller et al., 2004). Shirtcliff
and co-workers (2002) published a study which appears to cast doubt on the veracity of this
correlational relationship in females, stating that regardless of assay method, salivary T levels
are modestly correlated with serum levels for males but not necessarily females. The absolute
concentration, whilst reflecting accurately the unbound fraction in the plasma (and also the
fraction which is not bound to SHBG) is approximately twice the concentration of free-T in
plasma, in contrast to the findings in male subjects (Baxendale, Jacobs & James, 1982). One ma‐
jor implication of these findings is that substitution of saliva for serum T levels in at least bio-
behavioural studies may estimate the T-behaviour relationship differently for females than
males because substitution of saliva assay results for serum values markedly underestimates
known T-behaviour associations. In addition, there might be some ethnic variation in total and
free T concentration in that Heald et al. (2003) found that both total and calculated free T were
lower in Pakistani men than in Europeans.
4.2. Contamination of salivary samples
Clinical researchers have established that collection techniques can affect the integrity of
salivary samples, which subsequently interferes with ability to accurately determine hor‐
mone levels. For example, given the difference in T concentration between blood and saliva‐
ry samples, leaking of blood or serum into the mouth (i.e. due to gum disease, injury,
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consuming very chewy meals, caffeine intake, or vigorous cleaning) can affect the integrity
of quantitative estimates of salivary concentrations (Granger et al., 2004; Lac et al., 1993). In
response to a question about the incidence of haemoglobin contamination in salivary sam‐
ples, at a round table discussion on assay development and collection procedures (Tenovus
workshop, 1982), Schürmeyer suggested that researchers might reasonably expect a contam‐
ination incidence of around 5-10%. The majority of bio-behavioural studies investigating the
role of T in women propose that single time-point or very limited sampling is sufficient.
Whilst this issue is explored in more detail later in this chapter, it is worth noting here that
potential contamination of salivary samples by blood further complicates the use of single
samples. In addition, it is noted that where samples have been found with aberrant levels,
researchers have on occasion been treated by diluting the samples (i.e. Gladue et al., 1989).
Whilst this step may be appropriate for male salivary samples, dilutions of female salivary
samples which may already contain levels of T at the utmost sensitivity of the assay are ren‐
dered un-determinable.
Whilst the contamination of salivary samples by blood is widely recognized as a potential
problem in the scientific fields driving assay development there appears to be something of
a malaise regarding the issue in a wide range of bio-behavioural studies. Indeed, with only a
handful of notable exceptions a large number of authors have neglected to report how they
have dealt with this serious confound. In contrast, Mazur et al. (1980, 1987) and Gladue et al.
(1989) paid careful attention to the issue of contamination, adopting what, at the time, must
have appeared a sound approach. In utilising measurement strips called Hemastix® they at‐
tempted to ascertain which, if any, of their salivary samples may have become contaminated
with blood. Unfortunately, Kivlighan et al. (2004) cast doubt on the suitability of this ap‐
proach and reported that the confounding effects of blood leakage cannot be adequately
screened or controlled by visual inspection of sample discoloration or using the Hemastix®
approach. Other methods have recently been developed to assess blood contamination in
salivary samples. For example, Salimetrics now offer an assay to determine blood contami‐
nation in salivary samples (Schwartz & Granger, 2004), although this approach adds sub‐
stantially to the cost of assaying samples. Perhaps the best approach to reducing blood
contamination is avoiding its occurrence in the first place. In our own lab, and following
suggestions by Adlercreutz (1990), our subjects were asked to adhere to a number of steps
including refraining from brushing their teeth prior to sample collection, rinsing their
mouths thoroughly several times prior to collection, not consuming large meals, and not
smoking or drinking caffeine. These steps effectively reduced the amount of samples seen in
the assays with abnormal levels; indeed following these steps parallel to detailed instruc‐
tions enhanced collection to the extent that blood contamination in well over 10,000 samples
was effectively reduced to an incidence of below 1%.
4.3. Collection methods
With the increased use of salivary measures in clinical practice, bio-behavioural and clinical
research, several research teams have sought to advance our understanding of the circum‐
stances and conditions that may influence the validity of salivary assessments (e.g. Lipson &
Ellison, 1989; Shirtcliff et al., 2001). The use of a range of stimuli has been reported to stimu‐
late salivary flow where necessary; i.e. paraffin wax, rubber bands, sugar-free gum, cotton
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swabs, and citric acid (Malamud & Tabak, 1993; Navazesh, 1993). Granger and co-workers
(2004) found that materials commonly used in the literature to absorb saliva (cotton and pol‐
yester swabs) or stimulate saliva (powdered drink-mix crystals, citric acid and chewing
gum) have the potential to change salivary T results. Typically, saliva is collected by having
a participant deposit between 3-5mL into a collection container (less may be required in
some circumstances); this step is usually reported as taking between 3-8 minutes. The saliva
is then stored frozen prior to assay. While clinical subjects may be willing and able to pro‐
vide un-stimulated samples that can be immediately frozen, this protocol is often unpracti‐
cal for field collection (Lipson & Ellison, 1989). As such, collection of saliva samples under
these conditions may necessitate certain changes from common clinical practices. Although
collection of saliva is often referred to as un-stimulated, this is somewhat misleading. If the
salivary gland is un-stimulated it does not produce saliva; what is meant essentially is saliva
produced by minimal stimulation (Read, 1989). Small amounts of saliva can be collected
without the need to externally stimulate production, but the amount usually collected often
requires subjects to stimulate saliva production in some way. This issue is particularly perti‐
nent when investigating changes in concentration of salivary hormones over a certain peri‐
od of time or prior to competition, where time constraints exist and feelings of stress or
anxiety may make saliva production more troublesome. We have optimised our own saliva‐
ry samples collection method (see Table 1) that ensures the quality of saliva, reproducibility,
minimises blood contamination and stress during collection.
A Precautions
DO NOT exercise 24 hours prior to or on the day of salivary sample collections. (Exercise is defined as anything more
than low-moderate physical activity e.g. swimming, cycling, yoga, sex etc.)
DO NOT consume alcohol 24 hours prior to or on the day of salivary sample collections or drink coffee, milk, yoghurt
or meals within 45mins of collection
Each time you collect a saliva sample the method should be identical.
Procedure:
B Step by step guide to successful saliva sample colection
Step 1 - Do not eat or brush your teeth 60 minutes prior to saliva sample collection.
Step 2 - Rinse and swill mouth out thoroughly three times with tap or bottle water.
Step 3 - Chew a quarter of a stick of sugar free gum provided, as this will aid the production of saliva.
Step 4 - Retain the sugar free gum in your mouth, and spit away the first mouthful of saliva into the waste container
provided. This will remove unwanted cellular elements in the mouth and from the chewing gum.
Step 5 - Continue chewing the gum and spit into the collection container provided, until you have deposited 3-5
millilitres (ml) of saliva. Ensure the cap is replaced tightly.
Step 6 - Please mark the date and time of sample on the label of the collection container.
Step 7 - Please store saliva samples in the fridge 4˚C. Samples will then be collected by the researcher and frozen until
analysed.
Table 1. Optimised in-house method of salivary samples collection
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4.4. Storage of saliva samples
It is now known that bacterial growth can occur if saliva samples are stored above 4˚C (i.e.
at room temperature) for extended periods of time. In a recent report, it was found that bac‐
terial growth in saliva increased by incubation at room temperature over 10 days, and this
caused a significant decrease in salivary levels of both cortisol and T (Whembolua et al.,
2006). Some workers have shown that salivary steroid levels (cortisol, progesterone and 17-
OH-P) decreased significantly in the course of 3 weeks under different storage conditions
(native or centrifuged saliva, saliva with triflouroacetate and saliva combined with 0.05%
NaN3), and that the decrease was clinically significant from the second week onwards
(Groschl et al., 2001). After repeated freezing and re-thawing, only cortisol decreased signifi‐
cantly (p<0.001) presumably due to enzymatic conversion to metabolites. On the other hand,
a study by Granger et al. (2004) investigating the week-to-week change in salivary T levels
of samples stored at 4˚C for 4 weeks, -20˚C and -40˚C up to 24 months found that there was
a linear increase in T levels across the 4 weeks for samples stored at 4˚C (R2=0.88, p<0.05). By
the end of 4 weeks, there was an increase of 330% in T concentration using a Salimetric as‐
say. However, they reported a dramatic decrease in measured T levels over the 6 months
and 24 months in pooled samples stored at -20 and -40˚C (R2=0.85, p<0.05). Clearly, in order
for researchers to have confidence in their assay results a good deal of attention has to be
paid to issues of collection, storage and compliance.
5. Direct vs. In-direct technique
Solid phase and coated-technology assays can adopt either a direct or an in-direct approach
to determining levels of T. Whilst several assays, including commercially available kits, em‐
ploy a direct method (that is, salivary samples are not treated in any way prior to assay)
there are a number of limitations with this approach, especially when examining female an‐
drogens. Whilst the benefits of utilising saliva over serum have previously been described,
saliva is a far from inert substance; it contains a variety of contaminants, such as bacteria,
leukocytes, mucins, and very importantly for enzyme assays, endogenous enzymes. All of
which can interfere with assays based on the ELISA technique. As a consequence, salivary
samples are rendered extremely susceptible to interfering agents such as pH imbalance
which yields results that are, unpredictably, either too high or low (alkaline samples, for ex‐
ample, tend to yield low results). Schwartz et al. (1998) reported that when pH falls below 4
or rises above 9, then assay performance is likely to be compromised. At a round table dis‐
cussion of sex hormones and corticosteroid assays, Adlercreutz (1990) citing a range of stud‐
ies, noted that T assays do not work well in non-extracted plasma. Moreover, Jones et al.
(2004) reported that some samples from female subjects gave falsely high results when
measured with direct immunoassay.
Taib et al. (2003) found that 7 out of 10 immunoassay kits tested had overestimated T concen‐
trations by up to 46%, and that the target values were missed by 200-500%. This has prompt‐
ed some authors to doubt the validity of female T assays and suggest perhaps guessing levels
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in women to be cheaper and more accurate! (Herold & Fitzgerald, 2003). However, Dabbs and
colleagues (1995) reported on the reliability of salivary T assays evaluated by nine laborato‐
ries and found acceptable overall agreement (r=0.87 for men and r=0.78 for women). We sug‐
gest that one of the reasons commercial assays invariably produce T results that appear high
compared with in-house protocols is because of the cross-reactivity with DHEA/DHEA-S. The
importance of the cross-reactivity findings depends not only on the % cross-reactivity, but on
the relative concentration of the compound compared against T. For example, DHEA-S oc‐
curs in plasma at approximately 500 times the amount of T. Hence, a cross-reactivity of 0.72%
is potentially of more importance than the 2.3 % cross-reactivity found in DHT, which occurs
at levels below T in plasma. Using the extraction procedure removes the ability of DHEA-S to
interfere with the ‘in-house’ assay optimised in our laboratory.
6. Development of ELISA based assays for the measurement of
testosterone in saliva
A simple, reliable, easy to perform, sensitive and highly specific ELISA type assay for the
measurement of female salivary T has been developed in our lab and utilized in several
wide-ranging research projects investigating T levels in the menstrual cycle, circadian
rhythm and bio-behavioural studies. This has enabled us to screen large number of samples
within a short time at relatively low cost and with high sensitivity and assured specificity.
The principle of the salivary T assay optimised in our laboratory is based on the in-direct,
competitive binding technique (Al-Dujaili, 2006; Al-Dujaili et al., 1988; O’Sullivan et al.,
1979). Essentially, the T present in salivary samples competes with a fixed and limited
amount of T coated on the micro-titre plate, for binding sites on an antibody. Because the
concentration of the T coated to the wells is held constant, while the concentration of T in
the salivary samples vary, the amount of enzyme labelled second antibody bound to the first
antibody is inversely proportional to the concentration of the unlabelled analyte present in
the sample.
Extensive experimentation was conducted in our laboratory to optimise this assay. Because
of the often extremely low levels of T in female saliva, one of the particular requirements for
quantitative determination is that the assay be especially sensitive. However, the ELISA
process sits within a complex web of inter-locked parameters, and achieving this sensitivity
requires a constant balancing act between reagents and conditions to arrive at and maintain
the final protocol. For example, one of the ways to minimise the impact of interfering factors
is to extract the samples prior to assay. In line with guidelines taken from Al-Dujaili et al.
(1988) all assay reagents and conditions have been optimised to produce the required sensi‐
tivity, precision, accuracy and reliability including the amount of testosterone-bovine serum
albumin (BSA) conjugate needed to coat the plate, volume of sample, amount of antibody,
incubation temperature and incubation times. Below are our optimized protocols for sample
preparation, plate preparation and ELISA procedure:
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6.1. Sample preparation
1. Frozen samples are thawed, centrifuged at 3500rpm for 10mins, and aliquoted.
2. Aliquots centrifuged at 6000rpm for 2mins.
3. 0.5mL of sample combined with 4mL of diethylether.
4. Vortex mix for 10mins and freeze at -80˚C.
5. Decant unfrozen ether and place in 45˚C water bath until evaporated under nitrogen
gas.
6. Reconstitute with 0.5mL assay buffer.
7. Stand at room temp for 30mins and finally vortex mix to equilibrate.
6.2. Plate preparation
1. Coat plates with T conjugate and leave to incubate overnight at 4˚C
2. Wash three times with wash buffer
3. Block for 1hr at 37˚C
4. Discard blocking buffer
6.3. Optimized ELISA Procedure
1. 100µL of standard and previously extracted and reconstituted sample into wells in du‐
plicate. Standards run at 0.00, 1, 5, 10, 50, 250, 1000pg/mL
2. Add 100µL of antibody in assay buffer
3. Shake and incubate at 37˚C for 1hr
4. Discard and wash 4 times
5. Add 100µL of enzyme (horseradish peroxidase- linked second antibody)
6. Shake and incubate at 37˚C for 1hr
7. Discard and wash 4 times
8. Add 100µL of substrate (tetramethylbenzidine)
9. Incubate at room temperature for 15mins
10. Add 50µL of stop solution (H2SO4)
11. Read at 450nm on MRX Dynex plate reader
The validity of the salivary assay for T was confirmed by Al-Dujaili (2006) using the same
antibody and technique in urine and additionally by the correlation between the results ob‐
tained with the in-house ELISA and those assayed by Salimetrics ELISA kit (Salim ELISA =
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1.12x In-house ELISA – 0.042, R2 = 0.95, n= 58). Cross-reactivity data with major interfering ste‐
roids were minimal (see Table 2) except for testosterone-3-glucuronide (58.8%), dihydrotes‐
tosterone (2.3%) and androstenedione (4.6%). The average recovery of T in this assay was
104.0% (range 97.5% to 110%). The average intra-assay coefficient of variation was 5.78%. In‐
ter-assay imprecision of 8.7% was determined from the mean of averaged duplicates for 50
separate runs for male and female aliquots. Both inter and intra assay coefficients of varia‐
tion are at levels comparable with the best commercially available assay kits. Assay sensitiv‐
ity was determined and an un-related t-test revealed the differences between the zero
standard and 0.5 pg/mL concentration were significantly different: t (1, 11) = 9.098, p<0.001.
By this method the assay sensitivity is 0.5 pg/mL(1.74 pmole). The working sensitivity of the
assay, corresponding to the mass of testosterone required to give a decrease in the %B of
tracer of 2.5SD of the zero point signal was 1.24 pg/mL(4.33pmole). See typical standard
curve in figure 1. The applications of our salivary T ELISA can be seen in a wide-range of
clinical and bio-behavioural studies (e.g. Moore at al., 2011; Conway et al., 2007; Deady et
al., 2006; Sharp & Al-Dujaili, 2010). In addition, applications of the assay are discussed in
sections 8 and 9 of this chapter.
Steroid hormone % Cross- reactivity
Testosterone
Testosterone-3-glucuronide
100
58.8
Nandrolone 12
Dihydrotestosterone 2.3
Androstenedione* 4.6
DHEA 1.05
DHEA-sulphate* 0.72
Cortisol 0.001
Cortisone 0.03
Pregnenolone 0.05
Progesterone 0.02
Corticosterone 0.24
Prednisolone 0.3
Estradiol-17B 0.52
11-Deoxy-Cortisol 0.2
17-OH-Progesterone 0.02
11-deoxy-Corticosterone 0.06
Cholesterol 0.04
Table 2. Cross-reactivity between Testosterone and related steroid hormones
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Salivary testosterone standard curve
(mean ±1SD, N=10)
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Figure 1. Typical testosterone ELISA standard curve (mean with SD, N=10)
7. Female salivary testosterone: Single vs. multiple sampling
Establishing a baseline for salivary T is not entirely straightforward. Whilst T production is
partially under genetic control (Meikle et al., 1988) it is also responsive to a range of biologi‐
cal, environmental, and psychosocial stimuli; the relative influences of which are not yet
fully understood, in either males or females. Amongst those factors identified as having a
role in modifying T levels are: fasting, diet, sexual activity, alcohol, competition, behaviour
intended to increase status, aggression, physical exercise, cognition, stress, immune func‐
tion, and mood. In line with this, T concentrations have been shown to vary with time of
day (Ahokoski et al., 1998; Walker et al., 1980), season of the year (Dabbs, 1991), sexual activ‐
ity (Morris et al., 1987), and they fluctuate, in males at least, in a pulsatile fashion over mi‐
nutes and hours (Veldhuis et al., 1987). Moreover, among women, T concentrations are
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thought to increase around the middle of the menstrual cycle (Massafra et al., 1998; Vermeu‐
len & Verdonck, 1976; section 9 of this chapter).
Dabbs (1990) encapsulates some of the difficulties in designing suitable salivary sampling
regimens when he states, ‘...variability introduces error into behavioral studies, where stable
measures are needed to characterise individual differences and changes over time. Without
more information on these changes one cannot know how many participants to run, how
many measurements to take, and when to take measurements’ (p.83). For a T baseline to be
meaningful additionally depends, at least in part, on what purpose it is required to serve. In
certain clinical practices, for example, researchers have advocated collecting single samples
each day over the course of a week and pooling the samples to provide a weekly average. In
order to ascertain if an individual has levels of T that might indicate a risk of a particular
clinical condition this approach is appropriate. However, when attempting to examine chro‐
nobiological changes in relation to behavioural indices this sampling protocol would be un‐
suitable.
Comparatively little accurate research is available concerning detailed daily patterns of T in
females; particularly the biologically active free and bio-available components, as measured
in saliva. In the absence of reliable information, studies investigating the relationship be‐
tween androgens and female behaviour have formulated methods that tend to employ ei‐
ther single time-point or very limited sampling protocols. However, given that females may
also experience temporal fluctuation in T levels, similar to males, this salivary sampling pro‐
tocol may be inappropriate. In order to address questions of salivary sampling schedules for
one of our research programmes in female hormone/dominance research, we sought to pro‐
vide a comprehensive picture of potential circadian activity and episodic fluctuation in fe‐
male salivary T over one and then two non-consecutive days.
7.1. Methodology
Subjects were seventy-three healthy females (age range=18-29 with a mean age of 23.5).
None were hirsute, had serious acne or were overweight. Particular attention was paid to
factors that can affect circulating SHBG levels (i.e. history of kidney or liver disease, restric‐
tion of calorific intake) and none of the participants has administered any form of hormonal
medication during the previous 9 months. Eight 4mL salivary samples were collected
throughout the course of the day; one every two hours from 9am until 11pm. Following the
same protocol, fifty-three healthy female participants (age range=18-28; mean=24.7) with a
history of regular menstrual cycles lasting between 26-34 days also collected saliva on a sec‐
ond non-consecutive day. T concentrations were determined utilising our ‘in-house’ ELISA,
described earlier in the chapter.
7.2. Findings
T concentration showed a circadian rhythm similar to that found in males. Perhaps more
importantly, throughout the course of the day T concentrations were highly variable with
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episodic fluctuation of individual data points exceeding 83% of 9am levels. Mean T concen‐
trations over day 1 and 2 were 140.5 and 148.2 picomoles/L respectively.
Consistent with findings from previous studies, and resulting at least in part from the
spread of samples collected across menstrual cycle phase, there was considerable inter-indi‐
vidual variation in levels of T. Even so, table 3 illustrates that within the group mean, female
participants demonstrate a clear circadian profile, with levels higher in the early morning
and lower at 9pm, before starting to rise at 11pm. In the current data set percentage change
from mean 9am levels reached a level of 34.4% at 9pm with individual percentage change
from mean 9am levels reaching over 100%.
9am 11am 1pm 3pm 5pm 7pm 9pm 11pm
T (pmole/L)
Mean (SEM)
205.8
(11.0)
0.188
(10.7)
176.2
(10.8)
176.1
(11.5)
152.4
(10.8)
150.6
(10.5)
136.2
(9.5)
141.4
(10.9)
Table 3. Female Circadian Salivary Testosterone (Mean ± SEM, n=71)
9am 11am 1pm 3pm 5pm 7pm 9pm 11pm
Day1 T (pmole/L)
Mean (SEM)
160.9
(13.8)
144.6
(12.1)
149.9
(12.7)
148.3
(13.0)
136.5
(10.8)
140.6
(12.0)
126.8
(12.1)
118.9
(13.4)
Day2 T (pmole/L)
Mean (SEM)
171.9
(14.9)
171.8
(12.6)
166.5
(12.9)
166.1
(13.2)
130.1
(12.9)
125.4
(12.1)
128.9
(12.6)
125.6
(11.1)
Table 4. Testosterone Over Two Non-Consecutive Days (Mean ± SEM, n=53)
Contrary to the oft-cited claim that T is less labile in the afternoons our own results indicat‐
ed that individual variability is at its most pronounced between 1pm and 7pm, which is the
time it has been suggested studies take place in order to account for circadian variation and
during which time 1 sample is presumed to represent basal levels. For study 2, Table 4 illus‐
trates that across both days T followed a circadian profile appears only marginally similar.
7.3. Implications
In utilising single salivary measurements as somehow representative of basal female T lev‐
els we argue that studies attempting to correlate biological markers with behavioral indices
have introduced a potentially serious confound into their methodological design. This con‐
found is occasioned not only by normal circadian activity which, when considered in isola‐
tion we propose may be the wrong component of analysis on which to base the design of
these studies, but results from the temporal fluctuation evident in individual salivary T. By
adopting a more comprehensive sampling regimen than has previously been available the
two studies reported here provide a more detailed representation of circadian activity in the
free component of female T. Study 1 revealed evidence of a pronounced, though far from
uniform, circadian profile in female T, the magnitude of which from 9am to 9pm was ap‐
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proximately 34%. In a study on circadian and menstrual variation Dabbs and de La Rue
(1991) reported that morning T levels were 80% higher than evening samples. The magni‐
tude of this circadian profile appears surprisingly large, however. It is, for example, much
greater than the male equivalent (Bremner et al., 1983) and more than double the magnitude
of our circadian findings. It is worth considering why.
Findings from early bio-behavioral studies attempting to assess the free (and/or bio-availa‐
ble) component T tended to suffer from limitations in the assay technology available to
them. In the case of the Dabbs and de La Rue study (ibid.) the assay performance appeared
to be a major limiting factor in placing any confidence in the findings. Not only did the ex‐
traction step recover only 85% of the original analyte, but within and between-assay coeffi‐
cients of variation (CV) of 13.4% and 14.8% respectively appear excessively high. Moreover,
with only two samples collected per day, the collection schedule was extremely limited. In‐
deed, rather than collect samples at predetermined times the participants followed their
own schedules. As such, collection of the evening samples had an 85-minute standard devia‐
tion. These limitations provide a basis for recommending caution when interpreting the
magnitude of their circadian findings.
The year before, Dabbs (1990) had written another paper on the circadian activity of T in
both men and women and found a much smaller circadian profile. With specific reference to
the female participants there were serious methodological anomalies. Data were presented
from three independent studies: one group of participants collected salivary samples at 7am
and 10am; a second group collected samples at 7am, 10am, and 10.30am. A final group col‐
lected samples at 10am, 4pm, and 10pm. Dabbs reported that female T levels were high in
the early morning followed by a drop in the afternoon and early evening: ‘Mean testoster‐
one concentration dropped about 50% from morning to evening for both sexes, with largest
drops early in the day’ (p.83). However, in creating a circadian profile, the data from these
separate studies were combined. In adopting this approach Dabbs fashioned a situation
whereby a 7am sample for subject A must have been compared against a 10pm sample from
subject B. Given the widespread acknowledgment of, often extreme, inter-individual varia‐
tion in T levels, this procedure seems curious, at best. Moreover, despite earlier in the paper
providing several references which pointed to the fluctuation of hormone levels with time of
year, the data Dabbs collected, and subsequently combined, were collected at differing times
of the year (autumn and spring). Indeed, as Dabbs notes, the results emanated from separate
studies in which ‘Data were collected over a 2½ year period’ (p.83). Concerning the validity
of findings from these studies there are additional questions concerning the assay perform‐
ance and procedures. Firstly, in choosing to analyse aliquots of differing amounts of saliva
(from 0.05mL to 0.4mL) Dabbs effectively altered the concentration of T being determined.
He proceeded to suggest that the assay was run under analogue conditions (that is, one
standard curve is provided and against which all results are determined). Secondly, the as‐
say performance itself had an inter-assay variation in excess of 20% after recovering only
80-85% of the analyte following extraction. If these events were not problematic enough,
Dabbs states ‘There were changes in assay materials and in lab technicians and procedures
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over the course of the studies’ (p.84). We argue, that these limitations essentially render the
results impossible to interpret.
Interestingly, and we would argue critically, Dabbs makes the following point, ‘This kind of
variability should give us pause in working with single measurements from each subject,
where it is not possible to recognise a score as deviant from a subject’s mean’ (1990, p.85). In
attempting to determine the validity of utilising single salivary samples for determining
baselines there are two issues that arise from this comment. Dabbs appears to be suggesting
here that single time-point sampling can be problematic, if for no other reason than assay
techniques can and do throw up erroneous results that can be extremely difficult to detect
unless they are considered in relation to other scores from the same subject. The second is‐
sue is still whether circadian variation or episodic fluctuation confounds study design. It is
not possible to make a judgement based on these two studies; firstly because of the consider‐
able limitations in the study (design, measurement, methodology, interpretation) but also
due to the lack of a comprehensive sampling regimen. It is further worth noting that Dabbs
(1991) appear to contradict his earlier position, stating ‘…single measurements are reliable
enough for use in behavioral research’ (p.815).
In order to control for circadian activity several authors have indeed attempted to collect sam‐
ples during the course of the afternoon, when T levels have been assumed to be less labile than
in the mornings. In this regard Booth et al. (1989) state that ‘…it is helpful that matches are
played in the afternoon’ (p.558). Echoing this theme, Mazur, Booth, and Dabbs (1992) made
explicit reference to their attempts to ‘…ensure that reported effects are not artefacts of…diur‐
nal variation’ (p.72). Recently, a study on the relationship between T and personality charac‐
teristics in which single T measures were collected, Sellers et al. (2007) stated ‘To minimize the
effects of diurnal fluctuations in T levels, all participants were assessed between the hours of
Noon and 4pm’ (p.5). Zitmann and Nieschlag (2001) put forward an alternative proposal ar‐
guing, in their review paper of T and behavioral characteristics, that T samples should be col‐
lected during the morning in order to minimise the effects of diurnal variation. Of the three
published hormone-competition studies involving female participants, Mazur et al. (1997)
claimed that by collecting samples between 1pm and 10pm they had effectively controlled for
diurnal variation in T, which they clearly had not.
As a result of the more comprehensive circadian profile from our own data we are able to
demonstrate that, far from being relatively stable, women experience considerable moment-
to-moment variability in T levels. Even so, within the group mean of study 1 the significant
differences generally existed between time points at the beginning of the day and late after‐
noon (i.e. 5pm) onwards. One interpretation of this finding would be that single measure‐
ments, especially if collected during early to mid-afternoon, would suffice in bio-behavioral
research; collection at one moment in time being likely to yield much the same T level as any
other. However, in the present study the lack of a statistically significant difference between
T levels in the afternoon (between 1pm and 5pm) owes as much to the high standard devia‐
tions produced by the often extreme inter-individual variation as it does to a lack a differ‐
ence in levels of T between time points. It is our contention, therefore, that when considered
in isolation, mean circadian data may mislead researchers into believing that single sam‐
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pling is appropriate in the design of bio-behavioral studies. We maintain that the episodic
fluctuation (or, perhaps more correctly, random variability as the mechanism for this fluctu‐
ation is currently unknown in females) occurs at an order of magnitude that reduces confi‐
dence in the stability of a single salivary sample. It is for this reason we propose researchers
utilize multiple samples in the determination of baseline T. Indeed, as Riad-Fahmy (1982)
note, ‘The wide episodic fluctuations in circulating steroid levels make analysis of single
samples useful only in screening procedures’ (p.367).
7.4. Reliability across days
Dabbs (1990) reported correlations for female T across two consecutive days as ranging from
r=.55 though r=.73. Study 2 sought to examine the stability of T levels on two non-consecu‐
tive days demonstrated the relative lack of stability in levels of free T providing evidence
that, contrary to earlier reports, the day-to-day stability of female T may not be especially
high. In particular, the reliability between those subject who collected data on day 4 and
then 14 of their cycle the reliability is, at some time points, low. There is some question as to
whether levels of free T change across the menstrual cycle. Several studies have reported
that T varies in a predictable manner throughout the course of a menstrual cycle (Alexander
et al., 1990; Bloch et al., 1998), although the magnitude and subsequent relationship to be‐
haviour is, at present, unclear and we address this in the following section. In a study exam‐
ining plasma T changes across the menstrual cycle, Vermeulen and Verdonk (1976) stated,
‘It is evident from this study that T…plasma levels do show statistically significant cyclical
variations with maximal variations around ovulation’ (p.493). Just over ten years later this
finding was echoed in a study by Morris, et al. (1987), in which they indicated a rise in T
levels around the mid- point of the cycle. Dabbs and de La Rue (1991), whilst finding a mid-
cycle rise in salivary T, suggested that, as this variation was smaller than circadian variation,
‘Menstrual cycle effects can be ignored in most research relating psychological and behav‐
ioural variables to individual differences in testosterone’ (p.182). Our data appear to cast
doubt on these recommendations.
In providing a more comprehensive profile of the temporal activity of female salivary free T
the two studies reported here deal with an issue not satisfactorily addressed in the extant
literature. Study 1 demonstrated that not only is there a distinct circadian rhythm but indi‐
vidual temporal variability can be pronounced. We contend it is this temporal variability
that researchers need to account for in the design of salivary sampling protocols, and not
only circadian activity. Study 2 demonstrated that this temporal profile, whilst similar over
non-consecutive days 48hrs apart, reveals low reliability when samples are collected on
more disparate occasions. Hence, a sample collected at 10am on day 1 may well not corre‐
spond particularly closely to a sample collected at 10am on a second day, especially if those
days occur during different phases of a menstrual cycle. And yet, this is precisely the type of
sampling regimen evident in the hormone-competition literature (e.g. Bateup et al., 2002).
Combined, these data support the position that our understanding of the relationship be‐
tween T and behavior in women is seriously hindered by the use of single-time point sam‐
pling methodology. Hence, over and above reporting evidence of circadian activity, the
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highly erratic nature of female salivary T levels throughout the day is an important consid‐
eration in sampling design. Indeed, these results suggest that females also exhibit episodic
or random fluctuation at levels which call into question the use of single T measurement in
female bio-behavioural studies.
8. Establishing female salivary testosterone circadian rhythm profiles in
the menstrual cycle: Evidence of decline during ageing
In an attempt to further our understanding of circadian and menstrual dynamics the aim of
the study was to establish circadian profiles and normal levels of salivary T in healthy wom‐
en from the age of 19 through 69 at 3 points during the menstrual cycle, by means of a high‐
ly sensitive ELISA (described in section 7). Also, we wanted to investigate whether salivary
T levels decline with age.
Five main groups of females: ages, 19-29, 30-39, 40-49 (pre and postmenopausal), 50-59 and
60-69 years were investigated. All subjects provided 8 saliva samples per day on the 4th, 14th
and 21st day of their cycle according to their first day of menses, and post-menopausal wom‐
en collected saliva samples on the 4th, 14th and 21st day of the calendar month. The women
were not on any medication including the contraceptive pill and HRT, and did not suffer
from any major illness. T levels were determined by our in-house ELISA method. The data
indicated that female salivary T concentration showed a circadian rhythm similar to that
found in males, although at lower levels (Fig. 2). Perhaps, more importantly, throughout the
course of the day T levels were highly variable with episodic fluctuations of individual data
points exceeding the 09.00 hours levels on some days (see Fig. 3). There was marked varia‐
tion in T concentration between day 4, 14 and 21 of the cycle, though not statistically signifi‐
cant except for the age group of 30-39 year (p<0.02,) (see Fig. 4). When a repeated measure
ANOVA with time and day as within subject factors and age group as between subject fac‐
tors was applied, it was found that there was a significant difference in salivary T levels for
age groups 19-29 and 40-49 years (p = 0.01), and between 30-39 and 40-49 years (p = 0.02). A
Bonferroni correction was used for multiple comparisons.
Normal ranges for salivary T in females from the age of 19 through 69 year old at 3 different
distinct days of the cycle (4, 14 and 21) for menstruating women, and 3 calendar days for
post-menopausal women have been established. The results indicate that female salivary T
concentration show a circadian rhythm similar to that found in males, although perhaps
more importantly, throughout the course of the day T levels were highly variable with epi‐
sodic fluctuations of individual data points exceeding the 09.00 hours levels. These findings
lead us to suggest that normal ranges of T should only be determined from multiple sam‐
ples as single measurements may be potentially misleading as they are subject to too much
error variance. This view was reported by the authors in another study (Sharp & Al-Dujaili,
2004) and supported by Hoffman (2001) who suggested that because of diurnal and monthly
variations, several steroid hormones need multiple samples to give meaningful results.
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Figure 2. Female Salivary daily Testosterone rhythm throughout the menstrual cycle for A) pre-menopausal
women (age group 19-29, 30-39 years) and B) postmenopausal women (age groups 44-49, 50-59 and 60-69). Some
pre-menopausal women 40-44 years data were included in the graph of 40-49 years. All data represent mean ±sem of
day 4, 14 and 21 of the cycle.
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Figure 3. Female salivary testosterone levels in women at 40-49 years showing episodic fluctuations of individual data
points exceeding the 09.00 hours levels on some days (Data are mean of 12 females).
Figure 4. Summary of Salivary Testosterone results in females: Average testosterone concentration per day in pmole.
(* = P< 0.05, ** = p< 0.01, *** = p< 0.001). Student paired t-tests were done between these groups and group
19-29years)
In terms of absolute salivary T levels obtained by our ELISA method and bearing in mind
the high specificity of the T antibody employed, the values seem to be somewhat higher
than those reported elsewhere, particularly for younger women. We believe that this could
be due to the fact that our ELISA might be measuring some of the bio-available T concentra‐
tion (i.e. the free fraction plus the albumin-bound T: Pardridge & Demers, 1991). A view
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supported by earlier findings by Ruutiainen et al. (1987) who found that concentrations of
salivary T (without chromatographic prepurification) in hirsute women exceeded free T in
plasma by 10-fold. However, Swinkels and co-workers (1991) found that salivary T levels
were 3-fold higher than plasma free T due to the metabolism of androgen precursors (e.g.,
androstendione) during passage through the salivary gland. We believe that both of the
above mechanisms may be involved.
Our results demonstrated an effect of age on salivary T similar to that found in serum in
which there is a significant decline in salivary T level between younger groups of females
and those after menopause and older groups. These results were also found by other re‐
searchers (e.g. Labrie et al., 1997). However, some workers (Burger, 2002) stated that serum
T does not change significantly in relation to the menopausal transition but it falls slowly
with age. Such difference could be explained by the fact that they were measuring serum
total T rather than the biologically active hormone. Another study by Campbell and Ellison
(1992) found that salivary T was higher in anovulatory cycles compared with ovulatory cy‐
cles, and that T levels tend to be higher at the midcycle phase.
The results of this study have clearly demonstrated that there was a significant decline in
female salivary T across age groups and particularly after the age of 39 years. These findings
are supported in a study by Labrie and colleagues (1997) in which they compared serum T
levels in women of 20-30 years old with 70-80 years old, and found that there was a marked
decline in C19 steroids in the older group with smaller changes after the age of 60 years.
Other studies (e.g. Zumoff et al., 1995; Longcope, 1998) have also shown a decline in serum
T after the age of 30 years and just before the menopause varying from 15-50%. We have
also shown that there was a significant drop in female salivary T concentration in post-men‐
opausal women compared to menstruating women within the age group of 40-49 years (p<
0.02 to p<0.05). However, Burger et al. (2000) showed no change in serum total T levels 5
years before and 7 years after the menopause. Our results, on the other hand, showed a
slight increase in salivary T at the age group of 60-69 years compared to other post-meno‐
pausal women. This was mainly due to 2 subjects (ages 61 and 64) who consistently exhibit‐
ed higher T values that could be due to undeclared use of HRT or non-compliance with
instructions. Several studies have shown possible vital roles for androgens - and in particu‐
lar T- in women (Synder, 2001; Braunstein, 2002; Burger, 2002). Specifically, to increase li‐
bido, increasing bone mineralization, effect on muscle mass and strength and sense of
general well being. We also think that it is absolutely necessary to assess female T before any
hormone replacement therapy, and our results demonstrate without doubt that some wom‐
en had seriously low T levels that might precipitate deleterious effects on the health and life
quality of these women.
In conclusion, our results suggest that females do exhibit episodic fluctuations in daily sali‐
vary T throughout the menstrual cycle, and there is marked variation in T concentration be‐
tween day 4, 14 and 21 of the cycle. Moreover, single T measurements appear to be of little
value representing only the level at the time they were collected. There is however, a signifi‐
cant decline in female salivary T after the age of 39 years. The data obtained will hopefully
allow clinicians to have much greater confidence in their ability to determine the necessity
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of androgen replacement therapy (HRT) for post-menopausal women and those with sus‐
pected insufficiency. It is extremely important for women embarking on taking any form of
HRT to consult their physician who can now assess by simple screening method the endoge‐
nous level of T in order to administer the correct dose of HRT. This might minimise any side
effects.
9. Summary
We commenced our chapter with an up-to-date revision on the role of testosterone (T) in
women’s health, illustrating both the complexity and breadth of physiological and psycho‐
logical actions. Although not exhaustive in scope it is clearly evident from these examples
that T can no longer be considered as male only hormone and a greater emphasis on the role
of T in female behaviours is warranted. Second, we described T production in females and
discussed recent advances in our understanding of mechanisms of action such as non-ge‐
nomic pathways. Here we also considered the importance of incorporating both free and
bio-available fractions in the measurement of salivary T. Third we discussed the use of sali‐
va as a diagnostic fluid and highlighted that despite its utility there are a number of prob‐
lems and challenges related to the collection, storage and measurement of androgens in
saliva, which researchers must be aware of if we are to have confidence in studies across
several disciplines and particularly in those bio-behavioural studies which seek to draw of‐
ten controversial inferences about the role of women in society based upon levels of circulat‐
ing T. Fourth we dealt with the assay technology generally and more specifically the
development and optimization of our own enzyme-linked immunosorbant assay (ELISA),
specifically designed for use in the quantitative determination of female salivary T. Finally,
we discussed the circadian dynamics of female salivary T. Very little research is available
about detailed daily patterns of T in females; particularly the biologically active free compo‐
nent, as measured in saliva. In the absence of reliable information, hormone replacement
therapy programmes and bio-behavioural studies involving female participants have tend‐
ed to formulate salivary sampling strategies taken directly from research involving males.
We were able to draw upon our own innovative work on the circadian dynamics of female T
to illustrate the limitations of single or limited time-point sampling by demonstrating the
large intra and inter subject variability of diurnal rhythms and further show that merely
sampling in the afternoon as a means of reducing error is fraught with complications. Our
findings allowed us to highlight the need for comprehensive multiple sampling design for
effective protocols. Following this examination of circadian dynamics we also described our
work on menstrual fluctuations in salivary and circadian dynamics across the lifespan,
which demonstrated the significant difference in T levels across the menstrual cycle and de‐
cline across age. We hope that the ELISA protocol described here, the challenges in measure‐
ment and collection discussed and our findings on circadian dynamics in women are of
some assistance to researchers in helping them reflect upon and design meaningful studies
involving women and T.
Steroids154
Author details
E.A.S. Al-DujailI1* and M.A. Sharp2
*Address all correspondence to: ealdujaili@qmu.ac.uk
1 Dietetics, Nutrition and Biological Sciences, Queen Margaret University, Edinburgh, UK
2 School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
References
[1] Adlercreutz, H. (1990) Use of sex hormone and corticosteroid assays in the diagnosis
of endocrine disorders in women: Introduction to a round table discussion. Proceed‐
ings of the 4th Symposium on the Analysis of Steroids (pp. 387-395), Pécs, Hungary.
[2] Adlercreutz, H., Höckerstedt, K., Bannwart, C., Bloigu. S., Hämäläinen, E., Fotsis, T.
& Ollus, A. (1987). Effect of dietary components, including lignans and phytooestro‐
gens on enterohepatic circulation and liver metabolism of oestrogens and on sex hor‐
mone-binding globulin (SHBG) Journal of Steroid Biochemistry, 27: 1135-1144.
[3] Ahokoski, O., Virtanen, A., Huupponen, R., Scheinen, H., Salminene, E., Kairisto, V.,
& Irjala, K. (1998). Biological day-to-day variation and daytime changes in testoster‐
one, follitropin, lutropin and oestradiol-17β in healthy men. Clinical Chemistry and
Laboratory Medicine, 36, 485-491.
[4] Al-Dujaili, E.A.S. (2006). Development and validation of a simple and direct ELISA
method for the measurement of urinary testosterone excretion. Clinica Chimica Acta,
364 (1-2): 172-179.
[5] Al-Dujaili, E.A.S., Denyer, M., Milne, C., Philo, R., Pritchard, J., & Allen, A. (1988)
Serozyme: A manual non-isotopic immunoassay system. In Immunometric assays; over‐
view & new developments, Proceedings of NEQAS meeting (1-8), Cardiff, Wales.
[6] Alexander, G.M., Sherwin, B.B., Bancroft, J., & Davidson, D.W. (1990). Testosterone
and sexual behaviour in oral contraceptive users and nonusers: A prospective study.
Hormones and Behavior. 24, 388-402.
[7] Allen, N.E., Key, T.J. (2000). The effects of diet on circulating sex hormone levels in
men. Nutrition Res. Reviews, 13(2): 159-184.
[8] Anderson, K.E., Rosner, W., Khan, M.S., New, M.I., et al. (1987) Diet-Hormone Inter‐
actions: protein/charbohydrate ratio alters reciprocally the plasma levels of testoster‐
one and cortisol and their respective binding globulins in man. Life Sciences, 40:
1761-1768
Female Salivary Testosterone: Measurement, Challenges and Applications
http://dx.doi.org/10.5772/53648
155
[9] Bachmann, G.A., Leiblum, S.R. (1991). Sexuality in sexagenarian women. Maturitas,
13: 45-50.
[10] Bateup, H.S., Booth, A., Shirtcliff, E.A., & Granger, D.A. (2002). Testosterone, cortisol,
and women’s competition. Evolution and Human Behaviour, 23, 181-192.
[11] Baxendale, P.M., Reed, M.J., & James, V.H.T. (1980). Testosterone in saliva of normal
men and its relationship with unbound and total testosterone levels in plasma. Jour‐
nal of Endocrinology, 87, 46.
[12] Baxendale, P.M., Jacobs, H.S., &James, V.H. (1982) Salivary testosterone: relationship
to unbound plasma testosterone in normal and hyperandrogenic women. Clin Endo‐
crinol (Oxf), 16(6): 595-603.
[13] Beral, V. (2003). Breast cancer and hormone-replacement therapy in the Million
Women Study. Lancet, 362: 419-27
[14] Berrino, F. et al. (2001) Reducing bioavailable sex hormones through a comprehen‐
sive change in diet: the diet and androgens (DIANA) randomised trial. Cancer Epi‐
demiology Biomarkers & Prevention Vol. 10: 25-33.
[15] Besch, N.F., Ruetzel, C.H., Younes, M.A., Huang, N.H., Besch, P.K., & Read G.F.
(1982). Non-chromatographic determination of salivary testosterone in women: In G.F.
Read, D. Riad-Fahmy, R.F Walker, & K. Griffiths (Eds.). Ninth Tenovus Workshop:
Immunoassays of Steroids in Saliva. (pp. 221-227), Cardiff, Wales: Alpha Omega,
1982.
[16] Booth, A., Shelley, G., Mazur, A., Tharp, G., & Kittok, R. (1989). Testosterone, and
winning and losing in human competition. Hormones and Behavior, 23: 556-571.
[17] Bloch, M., Schmidt, P.J., Su, T.-P., Tobin, M.B., & Rubinow, D.R (1998). Pituitary-
adrenal hormones and testosterone across the menstrual cycle in women with pre‐
menstrual syndrome and controls. Biological Psychiatry. 43, 897-903.
[18] Braunstein, G.D. (2002). Androgen insufficiency in women: Summary of critical is‐
sues. Fertility and Sterility, 77 (Suppl. 4), S94-S99.
[19] Bremner, W.J., Vitiello, M.V., & Prinz, P.N. (1983). Loss of circadian rhythmicity in
blood testosterone levels with ageing in normal men. Journal of Clinical Endocrinology
and Metabolism, 56 (6), 1278-1281.
[20] Brincat, M., Moniz, C.F., Kabalan, S., Versi, E., et al. (1987). Decline in skin collagen
content and metacarpal index after the menopause and its prevention with sex hor‐
mone replacement. Br J Obstet Gynaecol 94: 126-129.
[21] Brown, G.L., McGarvey, E.L., Shirtcliff, E.A., Keller, A., Granger, D.A., & Flavin, K.
(2008). Salivary cortisol, dehydroepiandrosterone, and testosterone interrelationships
in healthy young males: a pilot study with implications for studies of aggressive be‐
havior. Psychiatry Res. May 30;159(1-2):67-76.
Steroids156
[22] Broderick, J.E., Arnold, D., Kudielka, B.M., & Kirschbaum, C. (2003). Salivary cortisol
compliance: comparison of patients and health volunteers. Psychneuroendocrinology,
29: 636-650.
[23] Burger, H.G. (2002). Androgen production in women. Fertil. Steril., 77 (supplement
4), S3-S5.
[24] Burger, N., & Casson, P. (2004). The pathophysiology of androgens in women. In
Testosterone; action, deficiency and substitution, Nieschlag, E & Behre HM (Eds), 4th
edition, Cambridge, page 543-569.
[25] Burger, H.G., Dudley, E.C., Cui, J., Dennerstein, L., & Hopper, J.L. (2000). A prospec‐
tive longitudinal study of serum testosterone, dehydroepiandrosterone sulphate and
sex hormone-binding globulin levels through the menopause transition. J Clin Endo‐
crinology Metab., 85, 2832-8.
[26] Campbell, B.C. & Ellison, P.T. (1992). Menstrual variation in Salivary Testosterone
among regularly cycling women. Hormone Research, 37, 132-136.
[27] Cardoso EM, Contreras LN, Tumilasci EG. et al. (2011) Salivary testosterone for the
diagnosis of androgen deficiency in end-stage renal disease. Nephrol Dial Transplant
26(2): 677-683
[28] Castoria, G., Lombardi, M., Barone MV, Bilancio A, et al. (2003). Androgen-stimulat‐
ed DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional re‐
ceptor action. J Cell Biol. 161(3):547-556
[29] Christiansen, K. (2004). Behavioural correlates of testosterone. In Testosterone: Actions, de‐
ficiency and substitution, Nieschlag E and Behre HM (Eds), 3rd Edition, page 125-172,
Cambridge University Press, Cambridge.
[30] Ciampelli, M., & Lanzone, A. (1998). Insulin and polycystic ovary syndrome: a new
look at an old subject. Gynecol Endocrinol. 12(4):277-292
[31] Collins, J.J. (2000). Salivary hormone testing: Science, benefits, limitations and clinical
applications. Anti-Ageing Medical News; Winter 2000 issue: 1-6.
[32] Conway, C.A. et al. (2007). Salience of emotional displays of danger and contagion in
faces is enhanced when progesterone levels are raised. Hormones and Behavior, 51(2):
202-206.
[33] Crook, D., & Seed, M. (1990). Endocrine control of plasma lipoprotein metabolism:
effects of gonadal steroids. Bailieres Clin Endocrinol Metab, 4: 851-875.
[34] Dabbs, J.M. Jr. (1990). Salivary testosterone measurements: reliability across hours,
days, and weeks. Physiology and Behavior, 48, 83-86.
[35] Dabbs, J.M. Jr. (1991). Saliva testosterone measurements: collecting, storing, and
mailing saliva samples. Physiology and Behavior 49 (4), 815–17.
Female Salivary Testosterone: Measurement, Challenges and Applications
http://dx.doi.org/10.5772/53648
157
[36] Dabbs, J.M., Campbell, B.C., Gladue, B.A., Midgley, A.R., Read, G.F., Swinkels, L.M.
& Worthman, C.M. (1995) Reliability of salivary testosterone measurements: a multi‐
center evaluation. Clinical Chemistry 41: 1581-1584.
[37] Dabbs, J.M. Jr. & de la Rue, D. (1991). Salivary Testosterone measurements among
women: relative magnitude of circadian and menstrual cycles. Hormones Research, 1
(35), 182-184.
[38] Davis SR (2011) Cardiovascular and cancer safety of testosterone in women. Curr
Opin Endocrinol Diabetes Obes. Jun;18(3):198-203.
[39] Davis, S.R. (1999). Androgen replacement in women: a commentary. Journal Clin En‐
docrinology Metab, 84(6), 1886-1891.
[40] Davis SR and Davison SL. (2012) Current perspectives on testosterone therapy for
women. Menopausal Medicine May 2012: S1-S4.
[41] Davis, S., & Tran, J. (2001). What are “normal” testosterone levels for women? J Clin
Endocrinol Metab, 86: 1842
[42] Davison, S.L., Bell, R., Donath, S., Montalto, J.G., & Davis, S.R. (2005). Androgen lev‐
els in adult females: changes with age, menopause and oophorectomy. J Clin Endocri‐
nol Metab 90: 3847-3853.
[43] Davy, B.M. & Melby, C.L. (2003). The effect of fibre-rich carbohydrates on features of
syndrome X. J AM Diet Assoc, 103: 86-96.
[44] Deady, D.K., Law Smith, M.J., Sharp, M.A., & Al-Dujaili, E.A.S. (2006). Maternal per‐
sonality and reproductive ambition in women is associated with salivary testoster‐
one levels. Biological Psychology, vol. 71, no. 1, 29-32.
[45] De Crée C, Lewin R and Ostyn M. (1990) The monitoring of the menstrual status of
female athletes by salivary steroid determination and ultrasonography. European
Journal of Applied Physiology and Occupational Physiology 60, Number 6: 472-477
[46] Edwards, R. (1985). Immunoassay: An Introduction. London: William Heinmann.
[47] Ekins, R. (1990). Hirsutism: free and bound testosterone 9letter). Ann Clin Biochem,
27: 91-93.
[48] Fausto-Sterling, A. (2000). Sexing the Body: Gender politics and the construction of sexual‐
ity. New York: Basic Books.
[49] Fettes, I. (1999). Migraine in trhe menopause. Neurology, 53(Suppl 1): S29-S33.
[50] Fix, C., Jordan, C., Cano, P., Walker, W.H. (2004). "Testosterone activates mitogen-ac‐
tivated protein kinase and the cAMP response element binding protein transcription
factor in Sertoli cells". Proc Natl Acad Sci USA 101 (30): 10919–10924.
[51] Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. (2007) Ovarian androgen production in
postmenopausal women. J Clin Endocrinol Metab. 92(8):3 040-3043.
Steroids158
[52] Gasperino, J. (1995). Androgenic regulation of bone mass in women. A review. Clin
Orthop 311: 278-286.
[53] Gavrilova N and Lindau ST (2009) Salivary Sex Hormone Measurement in a Nation‐
al, Population-Based Study of Older Adults. J Gerontol B Psychol Sci Soc Sci 64B
(suppl 1): 94-105
[54] Gladue, B.A., Boechler, M., & McCaul, K.D. (1989). Hormonal response to competi‐
tion in human males. Aggressive Behavior, 15, 409-422.
[55] Groh, H., Schade, K. & Horhold-Schubert, C. (1993). Steroid metabolism with intesti‐
nal micro-organisms. Journal of Basic Microbiology, 33, 59-72.
[56] Guay, A.T. (2002). Screening for androgen deficiency in women: Methodological and
interpretative issues: The Princeton consensus statement on definition, classification,
and assessment. Fertility and Sterility, 4 (Suppl. 4) S83-88.
[57] Guo, Z., Benten, W.P., Krucken, J., & Wunderlich, F. (2002). Non-genomic testoster‐
one calcium signaling. Genotropic actions in androgen receptor-free macrophages. J
Biol Chem, 277: 29600-29607.
[58] Granger, D.A., Schwartz, E.B., Booth, A., & Arentz, M. (1999). Salivary testosterone
determination in studies of child health and development. Hormones and Behavior, 35,
18-27.
[59] Granger, D.A., Shirtcliff, E.A., Booth, A., Kivlighan, K.T., Schwartz, E.B. (2004). The
trouble with salivary testosterone, Psychoneuroendocrinology, 29: 1229-1240.
[60] Groschl, M., Wagner, R., Rauh, M., & Dorr, H.G. (2001). Stability of salivary steroids:
the influences of storage, food and dental care. Steroids 66: 737-741.
[61] Haffner, S.M., Valdez, R.A., Mykkanen, L. et al. (1994). Deceased testosterone and
DHEA sulphate concentrations are associated with increased insulin and glucose
concentrations in non-diabetic men. Metabolism, 43: 599-603.
[62] Hammond, G.L., Nisker, J.A., Jones, L.A., & Siiteri, P.K. (1980). Estimation of the per‐
centage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. Jour‐
nal of Biological Chemistry, 255 (11), 5023-5026.
[63] Heald, A.H., Ivison, F., Anderson, S.G., Cruickshank, K., Laing. I,, & Gibson, M.
(2003). Significant ethnic variation in total and free testosterone concentration. Clin
Endocrinology 58: 262-266.
[64] Heinlein, C.A. & Chang, C. (2002). The roles of androgen receptors and androgens
binding proteins in non-genomic androgen actions. Mol Endocrinol. 16: 2181-2187.
[65] Herold, D.A., & Fitzgerald, R.L. (2003). Immunoassays for testosterone in women;
Better than a guess? Clinical Chemistry 49: 1250-1251
Female Salivary Testosterone: Measurement, Challenges and Applications
http://dx.doi.org/10.5772/53648
159
[66] Hickok, L.R., Toomey, C., Speroff. L. (1993). A comparison of estrified oestrogens
with and without methyltestosterone: effects on endometrial histology and serum
lipoproteins in postmenopausal women. Obstet Gynecol. 82: 919-924.
[67] Hiipakka, R.A., & Liao, S. (1998). "Molecular mechanism of androgen action". Trends
Endocrinol. Metab. 9 (8): 317–324.
[68] Ho, C.K., Stoddart, M., Walton, M., Anderson, R.A., & Beckett, G.J. (2006). Calculated
free testosterone in men: comparison of four equations and with free androgen in‐
dex. Ann Clin Biochem. 43(Pt 5):389-397.
[69] Hoffman, L.F. (2001). Human saliva as a diagnostic specimen. Journal of Nutrition,
131, 1621S-1625S.
[70] Hui, S.L., Perkins, A.J., Zhou, L., Longcope, C., Econs, M.J., & Johnston, C.C. (2002).
Bone loss at the femoral neck in perimenopausal white women: effects of weight
change and sex hormone levels. J Clin Endocrinol Metab, 87:1539-1543.
[71] Isidori, A.M., Giannetta, E., Greco, E.A., Gianfrilli, D. et al. (2008). Effects of testoster‐
one on body composition, bone metabolism and serum lipid profile in middle-aged
men: a meta-analysis. Clinical Endocrinology 63(3), 280–293.
[72] Jones, J., Murphy, E., Alaghband-Zadeh, J. (2004). Modified method for extracted assay
for female testosterone measurement on the Abbott Architect analyser. Conference Proceed‐
ings. 23rd Joint Meeting of the British Endocrine Societies with the European Federa‐
tion of Endocrine Societies, Brighton, UK.
[73] Kemeny, D.M. & Chantler, S. (1991). An introduction to ELISA. In D.M. Kemeny &
S.J. Challacombe. (Eds.). ELISA and other solid phase immunoassays: Theoretical and prac‐
tical aspects. Chichester: John Wiley & Sons.
[74] Kemeny, D.M. (1991). A Practical Guide to ELISA. Exeter: Pergamon Press.
[75] Kirkwood, T.B. (2005). Understanding the odd science of aging. Cell, 120: 437-447.
[76] Kivlighan, K.T, Granger, D.A., Schwartz, E.B., Nelson, V., Curran, M., & Shirtcliff,
E.A. (2004). Quantifying blood leakage into the oral mucosa and its effects on the
measurement of cortisol, dehydropiandrosterone, and testosterone in saliva. Hor‐
mones and Behavior, 46, 39-46.
[77] Kraemer, W., Volek, J.S., Bush, J.A., et al. (1998). Hormonal responses to consecutive
days of heavy resistance exercise with or without nutritional supplementation. J Ap‐
plied Physiology, 85 (4): 1544
[78] Kudielka, B.M., Broderick, J.E., Kirschbaum, C. (2003). Compliance with saliva sam‐
pling protocols: electronic monitoring reveals invalid cortisol daytime profiles in
noncompliant subjects. Psychosomatic Med, 65: 313-319
[79] Labrie, F., Belanger, A., Belanger, P., Berube, R., Martel, C., Cusan, L. (2006). Andro‐
gen glucuronides, instead of testosterone, as the new markers of androgenic activity
in women. J Steroid biochem Mol Biol, 99: 182-188.
Steroids160
[80] Labrie, F., Belanger, A., Cusan, L., Gomez, J.L., & Candas, B. (1997). Marked decline
in Serum concentrations of adrenal C19 sex steroid precursors and conjugated andro‐
gen metabolites during aging. Journal Clin Endocrinology Metab., 82 (8), 2396-2402.
[81] Labrie, F., Luu-The, V., Labrie, C., Pelletier, G., & El-Alfy, M. (2000). Intracrinology
and the skin. Horm Res. 54(5-6):218-229.
[82] Labrie, F., Luu-the V, Labrie, C., Belanger, A., Simard, J., Lin, S.X., & Peletier, G.
(2003) Endocrine and intracrine sources of androgens in women: inhibition of breast
cancer and other roles of androgens and their precursor DHEA. Endocrine Rev, 24:
152-182.
[83] Labrie F, Martel C, Balser J. (2011) Wide distribution of the serum dehydroepiandros‐
terone and sex steroid levels in postmenopausal women: role of the ovary? Meno‐
pause 18: 30-43.
[84] Lac, G., Lac, N., & Robert, A. (1993). Steroid assays in saliva: a method to detect plas‐
matic contaminations. Arch Int Phsiol Biochim Biophys, 101: 257-262.
[85] Laumann, E.O., Paik A, Rosen RC. (1999). Sexual dysfunction in the United States:
prevalence and predictors. Journal of the American Medical Association 281 (6): 537-544.
[86] Leiblum, S., Bachmann, G., Kemmann, E., Colburn, D., & Swartzman, L. (1983) Vagi‐
nal atrophy in the postmenopausal woman. The importance of sexual activity and
hormones. JAMA. 249(16):2195-2198
[87] Lepage, R. (2006). Measurement of testosterone and its sub-fractions in Canada. Clin‐
ical Biochem, 39: 97-108.
[88] Longcope, C. (1986). Adrenal and gonadal androgen secretion in normal females.
Clinic Endocrinol Metabolism, 15: 213-228.
[89] Longcope, C., Feldman, H.A., McKinlay, J.B., Araujo, A.B. (2000). Diet and sex hor‐
mone-binding globulin. J Clin Endocrinol Metab. 85(1):293-296
[90] Longcope, C., Hui, S.L., & Johnston, C.C. (1987). Free estradiol, free testostereone,
and sex hormone-binding globulin in perimenopausal women. J Clin Endocrinol Met‐
ab, 65: 513-518.
[91] Longcope, C. (1998). Androgen metabolism and the menopause. Semin Reprod. Endo‐
crinology, 16, 111-115.
[92] Lipson, S.F., & Ellison, P.T. (1989). Development of protocols for the application of
salivary steroid analyses to field conditions. Am J Human Biol, 249-255.
[93] Lösel, R.M., Falkenstein, E., Feuring, M., Schultz, A., Tillmann, H.C., Rossol-Haser‐
oth, K., & Wehling, M. (2003). Nongenomic Steroid Action: Controversies, Questions,
and Answers. Physiol Rev, 83: 965–1016.
Female Salivary Testosterone: Measurement, Challenges and Applications
http://dx.doi.org/10.5772/53648
161
[94] Luisi, M, Gasperi, M, Silvestri, D, Bernini, GP et al. (1982) Applicability of salivary‐
testosterone measurements for the follow-up of therapy of idiopathic hirsutism. Jour‐
nal of Steroid Biochemistry 17: 581–583
[95] Major C. V., Read S. E., Coates R. A., Francis A., McLaughlin B. J., Millson M., Shep‐
herd F., Fanning M., Calzavara L., MacFadden D., Johnson J. K., (1991) Comparison
of saliva and blood for human immunodeficiency virus prevalence testing. Journal of
Infectious Diseases, 163, 699-702.
[96] Malamud, D., & Tabak, L. (eds.) (1993) Saliva as a Diagnostic Fluid. New York: New
York Academy of Sciences.
[97] Mandel, I.D. (1993). Salivary diagnosis: Promises, promises. In D. Malamud, & L.A.
Tabak. (Eds.). Saliva as a diagnostic fluid. Annals of the New York Academy of Sciences,
694 (pp. 1-10). New York, NY: New York Academy of Sciences.
[98] Manni, A., Pardridge, W.M., Cefalu. W. et al. (1985). Bioavailability of albumin-
bound testosterone. Journal of Clinical Endocrinology and Metabolism, 61 (4), 705-710.
[99] Massafra, C., De Felice, C., Agnusdei, D.P., Gioia, D., & Bagnoli, F. (1998). Androgens
and Osteocalcin during the menstrual cycle. Journal of Clinical Endocrinology and Me‐
tabolism, 84 (3), 971-974.
[100] Matsumoto, A.M., Bremner, W.J. (2004). Serum testosterone assays - Accuracy mat‐
ters. J Clin Endocrinol Metab, 89: 520-524.
[101] Mazur, A. & Lamb, T. (1980). Testosterone, status, and mood in human males. Hor‐
mones and Behavior, 14, 236-246.
[102] Mazur, A., Susman, A.J., & Edelbrock, S. (1997). Sex difference in testosterone re‐
sponse to a video game contest. Evolution and Human Behavior, 18, 317-326.
[103] Mazur, A., Susman, A.J., & Edelbrock, S. (1997). Sex difference in testosterone re‐
sponse to a video game contest. Evolution and Human Behavior, 18, 317-326.
[104] Mazur, A., Booth, A., & Dabbs Jr., J.M. (1992). Testosterone and chess competition.
Social Psychology Quarterly, 55 (1), 70-77.
[105] McPhaul, M.J., Young, M. ( 2001). "Complexities of androgen action". J. Am. Acad.
Dermatol. 45 (3 Suppl): S87–S94
[106] Meikle, A.W., Stringham, J.D., Bishop, D.T., & West, D.W. (1988). Quantitating gen‐
entic and non genetic factors influencing androgen production and clearance rates in
men. Journal of Clinical Endocrinology and Metabolism, 67, 104-109.
[107] Mendel, C.M. (1989). The free hormone hypothesis: a physiologically based mathe‐
matical model. Endocrin Rev, 10: 232-274.
[108] Miller, K.K., Rosner, W., Lee, H., Heir, J., Sesmilo, G., Schoenfeld, D., & Kilbanski, A.
(2004). Measurement of free testosterone in normal women and women with andro‐
gen deficiency: comparison of methods. J Clin Endocrinol Metab, 89: 525-533.
Steroids162
[109] Moore, F.R, Al Dujaili, E.A.S., Cornwell, R.E., Law Smith, M.J., Lawson, J.F., Sharp,
M. & Perrett, D. I. (2011) Cues to sex- and stress-hormones in the human male face:
functions of glucocorticoids in the immunocompetence handicap hypothesis. Hor‐
mones and Behavior, 60: 269-274.
[110] Morris, N.M., Udry, J. R., Khan-Dawood, F., & Dawood, M.Y. (1987). Marital sex fre‐
quency and midcycle female testosterone. Archives of Sexual Behavior, 16 (1), 27-37.
[111] Navazesh, M. (1993). Methods for collecting saliva. In D. Malamud, & L.A. Tabak.
(Eds.). Saliva as a diagnostic fluid. Annals of the New York Academy of Sciences, 694 (pp
72-77). New York, NY: New York Academy of Sciences.
[112] Nieschlag, E., & Behre, H.M., (1998) eds. Testosterone: action, deficiency, substitution.
2nd ed. Berlin: Springer-Verlag, 1998:58-66.
[113] O’Sullivan, M.J., Bridges, J.W., & Marks, V. (1979). Enzyme immunoassay: a review.
Annals of Clinical Biochemistry, 16, 221-239.
[114] Overlie, I., Moen, M.H., Morkrid, L., Skjaeraasen, J.S., & Holte, A. (1999). The endo‐
crine transition around menopause- a five years prospective study with profiles of
gonadotropines, oestrogens, androgens and SHBG among healthy women, Acta Ob‐
stet Gynecol Scand 78: 642-647.
[115] Pardridge W.M., & Demers L.M. (1991). Bioavailable testosterone in salivary glands.
Clin Chemistry 37: 139-140.
[116] Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici B, Flamia R, Biscotti
M and Vicennati V (1995) Insulin regulates testosterone and sex hormone-binding
globulin concentrations in adult normal-weight and obese men Journal of Clinical En‐
docrinology and Metabolism 80, 654-658.
[117] Perry RJ, Mayo A, Deeb A, MacIntyre H, Wallace AM, et al (2005) Salivary testoster‐
one measurement for monitoring treatment of children with congenital adrenal hy‐
perplasia (CAH). Endocrine Abstracts 9: P143
[118] Pusateri, D.J., Roth, W.T., Ross, J.K. & Shultz, T.D. (1990). Dietary and hormonal eval‐
uation of men at different risks for prostate cancer: plasma and faecal hormone-nu‐
trient interrelationships American Journal of Clinical Nutrition, 51: 371-377.
[119] Quissell, D.O. (1993). Steroid hormone analysis in human saliva. Ann N Y Acad Sci.
694:143-145.
[120] Rako, S. (1998). Testosterone deficiency: a key factor in the increased cardiovascular
risk to women following hysterectomy or with natural ageing. J Women Health, 7:
825-829.
[121] Read, G.F. (1989). Hormones in saliva. Tenovuo, J.O. (Eds.). Human Saliva: Clinical
Chemistry and Microbiology. Boca Raton, FL: Press Inc.
[122] Riad-Fahmy, D., Read, G.F., Walker, R.F., & Griffiths K. (1982). Steroids in saliva for
assessing endocrine function. Endocrine Reviews, 3 (4), 367-395.
Female Salivary Testosterone: Measurement, Challenges and Applications
http://dx.doi.org/10.5772/53648
163
[123] Rinaldi, S., Geay, A., Dechauld, H., Biessy, C., Zeleniuch-Jacquotte, A., Kaaks, R.
(2002). Validity of free testostereone and free estradiol determinations in serum sam‐
ples from postmenopausal women by theoretical calculations. Cancer Epidemiol Bio‐
merkers Prev, 11: 1065-1071.
[124] Rock, C.L., Flatt, S.W., Thomson, C.A., Stefanick, M.L., Newman, V.A. et al. (2004).
Effects of a High-Fiber, Low-Fat Diet Intervention on Serum Concentrations of Re‐
productive Steroid Hormones in Women With a History of Breast Cancer. J Clin On‐
cology, 22: 2379-2387
[125] Rosner, W. (2001). An extraordinarily inaccurate assay for free testosterone is still
with us [Letter]. Journal of Clinical Endocrinology and Metabolism, 86 (6), 2903.
[126] Ruutiainen, K., Sannikka, E., Santti, R., Erkkola, R., & Adlercreutz, H. (1987). Salivary
testosterone in hirsutism: Correlation with serum testosterone and the degree of hair
growth. J Clin Endocrinol Metab, 64: 1015-1020.
[127] Sands, R. & Studd, J. (1995). Exogenous androgens in postmenopausal women. Am J
Med. 98: 76-79.
[128] Sarrel, P.M. (1998). Cardiovascular aspects of androgens in women. Semin Reprod En‐
docrinol, 16: 121-128.
[129] Schurmeyer, T., & Nieschlag, E. (1982). Salivary and serum testosterone under phys‐
iological and pharmacological conditions. In: Read GF, Riad-Fahmy D, Walker RF,
Griffiths K, editors.
[130] Immunoassays of steroids in saliva. Cardiff, Wales: Alpha Omega; 1982. pp 202–209.
[131] Schwartz, E.B., et al. (1998). Assessing salivary cortisol in studies of child develop‐
ment. Child Development. 69 (6): 1503–1513.
[132] Schwartz, E.B., & Granger, D.A. (2004). transferrin enzyme immunoassay for quatita‐
tive monitoring of blood contamination in saliva. Clinical Chemistry. 50: 654-656.
[133] Sellers, J.G., Mehl, M.R. & Josephs, R.A. (2007). Hormones and personality: Testoster‐
one as a marker of individual differences. Journal of Research in Personality. 41 (1):
126-138.
[134] Shakil, T., Ehsanul hoque, A.N., Husain, M., & Belsham, D.D. (2002). Differential reg‐
ulation of gonadotropin releasing hormone secretion and gene expression by andro‐
gens: membrane versus nuclear receptor activation. Mol Endocrinol, 16: 2592-2602
[135] Sharp, M.A. & Al-Dujaili, E.A.S. (2004). Application of testosterone ELISA for female
salivary samples: Circadian rhythm studies. Proceeding of American Endocrine Society’s
86th Annual Meeting, June, pp 539.
[136] Sharp, M.A. & Al-Dujaili, E.A.S. (2010). A Biological Basis for Status Competition in
Human Females. Society for Behavioral Neuroendocrinology, Toronto, Canada.
[137] Shibayama Y, Higashi T, Shimada K, Odani A et al. (2009) Simultaneous determina‐
tion of salivarytestosterone and dehydroepiandrosterone using LC–MS/MS: Method
Steroids164
development and evaluation of applicability for diagnosis and medication for late-
onset hypogonadism Journal of Chromatography B 877: 2615–2623
[138] Shirtcliff, E.A., Granger, D.A., Schwartz, E., & Curran, M.J. (2001). Use of salivary bi‐
omarkers in biobehavioral research: Cotton based sample collection methods can in‐
terfere with salivary immunoassay results. Psychoneuroendocrinology, 26:165-173
[139] Shirtcliff, E.A., Granger, D.A., & Likos, A. (2002). Gender differences in the validity
of testosterone measured in saliva by immunoassay. Hormon Behav., 42: 62-69.
[140] Simpson, R.E. (2002). Aromatisation of androgens in women: Current concepts and
findings. Fertility and Sterility, 77 (4), Suppl. 4, S6-S10.
[141] Sinha-Hikim, I., Arver, S., Beall, G., Shen, R. et al., (1998). The use of a sensitive equi‐
librium dialysis method for the measurement of free testosterone levels in healthy,
cycling women and in the human immunodeficiency virus infected women. Journal
of Clinical Endocrinology and Metabolism, 83 (4), 1312-1318.
[142] Slemend, C., Longcope, C., Peacock, M., et al. (1996), Sex steroids, bone mass and
bone loss. Aprospective study of pre- and postmenopausal women. J Clin Invest, 97:
14-21.
[143] Snyder, P.J. (2001) Editorial: the role of androgens in women. J Clin Endocrinol Metab,
86: 1006-1007.
[144] Somboonporn W, Bell R, Davis S. (2010) Testosterone for peri- and postmenopausal
women. In: The Cochrane Library, Issue 2, 2010. Chichester, UK: John Wiley & Sons,
Ltd.
[145] Somboonporn, W., Davis, S., Seif, M.W., Bell, R. (2006). Testosterone for peri- and
postmenopausal women. Cochrane Database Syst Rev:CD004509, The Cochrane Col‐
laboration, John Wiley.
[146] Sowers MF, J. L. Beebe, D. McConnell, John Randolph, and M. Jannausch (2001) Tes‐
tosterone Concentrations in Women Aged 25–50 Years: Associations with Lifestyle,
Body Composition, and Ovarian Status. Am J Epidemiol 153: 256–264.
[147] Swinkels, L.M., van Hook, H.J., Ross, H.A., Smals, A.G., & Benraad, T.J. (1991). Con‐
centrations of salivary testosterone and plasma total, non-sex-hormone-binding glob‐
ulin-bound, and free testosterone in normal and hirsute women during
administration of dexamethasone/synthetic corticotrophin. Clin Chemistry, 37:
180-185.
[148] Taieb, J., Benattar, C., Birr, A.S., & Lindenbaum, A. (2002). Limitations of Steroid De‐
termination by Direct Immunoassay. Clinical Chemistry, 48, 583-585.
[149] Taieb, J., Mathian, B., Millot, F., et al. (2003). Testosterone measured by 10 immuno‐
assays and by isotop-dilution gas chromatography-mass spectrometry in sera from
116 men, women and children. Clinical Chemistry, 49: 1381-1395.
Female Salivary Testosterone: Measurement, Challenges and Applications
http://dx.doi.org/10.5772/53648
165
[150] Teoh Y, Macintyre H, Ahmed F, Wallace M. (2005) Radioimmunoassay (RIA) method
for Salivary Testosterone: Reference ranges in children, adult men and adult women.
Endocrine Abstracts 9: P51
[151] Tremollieres, F., Pouilles, J.M., & Ribot, C. (1992). Postmenopausal bone loss. Role of
progesterone and androgens. Presse Med, 21: 989-993.
[152] Ullis, K., Ptacek, G., & Shackman, J. (1999). SuperT, New York: Fireside Books a divi‐
sion of Simon and Schuster.
[153] Veldhuis, J.D., King, J.C., Urban, R.J. et al. (1987). Operating characteristics of the
male hypothalamo-pituitary-axis: Pulsatile release of testosterone and follicle-stimu‐
lating hormone and their temporal coupling with leutinizing hormone. Journal of
Clinical Endocrinology and Metabolism, 65, 929-841.
[154] Vermeulen, A., Verdonck, L., & Kaufman, J.M. (1999). A critical evaluation of simple
methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinol‐
ogy and Metabolism, 84 (10), 3666-3672.
[155] Vermeulen, A. & Verdonck, L. (1976). Plasma androgen levels during the menstrual
cycle. American Journal of Obstetrics and Gynaecology, 125 (4), 491-494.
[156] Vermeulen, A. (1998). Plasma androgens in women. Journal of Reproductive Medicine,
43, 725-733.
[157] Vliet, E.L., & Davis, V.L. (1991). New prospectives on the relationship of hormone
changes to affective disorders in the perimenopause. Clin Issu Perinat Women's Health
Nurse, 2: 453-471.
[158] Vittek, J., L’Hommedieu, D.G., Gordon, G.G., Rappaport, S.C., & Southren, A.L.
(1985). Direct radioimmunoassay of salivary testosterone: correlation with free and
total serum testosterone. Life Sci., 37: 711-716.
[159] Wang, C., Catlin, D.H., Starcevic, B. et al. (2005). Low-fat high-fibre diet decreased
serum and urine androgens in men. J Clin. Endocrinol Metab., 90 (6): 3550-3559.
[160] Wellen JJ, Smals AG, Rijken JC, Kloppenborg PW, Benraad TJ. (1983) Testosterone
and delta 4-androstenedione in the saliva of patients with Klinefelter's syndrome.
Clin Endocrinol (Oxf). 18(1): 51-59.
[161] Whembolua, G.S., Granger, D.A., Singer, S., Kivlighan, K.T., & Marguin, J.A. (2006).
Bacteria in the oral mucosa and its effects on the measurement of cortisol, dehydroe‐
piandrosterone and testosterone in saliva. Hormones and Behvaior, 49, 478-483.
[162] White, C.M., Ferraro-Borgida, M.J., Moyna, N.M., McGill, C.C., et al. (1998). The
pharmacokinetics of intravenous testosterone in elderly men with coronary artery
disease. J Clin Pharmacol. 38(9):792-797.
[163] Writing Group for the Women's Health Initiative Investigators. (2002). Risks and
Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal
Steroids166
Results From the Women's Health Initiative Randomized Controlled Trial. JAMA,
288:321-333.
[164] Zitmann, M. & Nieschlag, E. (2001). Testosterone levels in healthy men and the rela‐
tion to behavioural and physical characteristics: facts and constructs. European Journal
of Endocrinology, 144, 183-197.
[165] Zumoff, B., Strain, G.W., Miller, L.K., & Rosner, W. (1995). Twenty four hour mean
plasma testosterone declines with age in normal premenopausal women. J Clin Endo‐
crinol Metab, 80: 1429-1430.
Female Salivary Testosterone: Measurement, Challenges and Applications
http://dx.doi.org/10.5772/53648
167

